CN105039359A - Virus-like particles of 16-type recombinant human papilloma virus and preparation method thereof - Google Patents
Virus-like particles of 16-type recombinant human papilloma virus and preparation method thereof Download PDFInfo
- Publication number
- CN105039359A CN105039359A CN201410683185.0A CN201410683185A CN105039359A CN 105039359 A CN105039359 A CN 105039359A CN 201410683185 A CN201410683185 A CN 201410683185A CN 105039359 A CN105039359 A CN 105039359A
- Authority
- CN
- China
- Prior art keywords
- protein
- hpv16l1
- pentamer
- seqno
- tag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to virus-like particles of 16-type recombinant human papilloma virus and a preparation method thereof. In particularly, a technical point of the invention aims to provide a polynucleotide gene fragment of a new encode-recombinant HPV16 L1 protein, a carrier containing the polynucleotide gene fragment, a host cell containing the carrier, HPV16 L1 fusion protein and a pentamer which are translated and expressed from the gene fragment, and VLP composed of the pentamer. The invention also discloses an application of the pentamer, the VLP protein and a vaccine composition composed thereof in preparation of a drug for preventing HPV16 infection.
Description
Technical field
The present invention relates to human papillomavirus
virus-like particleand preparation method thereof.More specifically, the present invention relates to a kind of pentamer and virus-like particle (Virus-likeParticle, VLP) and preparation method thereof of human mammilla tumor virus L 1 albumen of restructuring, and containing being somebody's turn to do
virus-like particlethe application of vaccine composition in prevention of human papillomavirus infection.
Background technology
Human papillomavirus (HumanPapillomavirus is called for short HPV), mainly through human body close contact, as the virus spread through sex intercourse, can cause the multiple proliferative epithelial lesion of the mankind, comprise papilloma (wart) and tumor-like lesion.Specifically, the disease that HPV brings out mainly comprises 3 large classes, the 1st class: the malignant changes such as the cancer of uterine neck, vagina, female vulva, penis and anus and the tumor of head and neck of some type.The cervical cancer patient of 100% is all that HPV infects and causes, the anus cancer of 90%, and the vulva of 40%, vagina and penis, the oropharynx of 12% and the mouth cancers of 3% infect owing to HPV.2nd class: benign lesion, as the Genital warts such as verruca plana, pointed condyloma, is a kind of sexually transmitted disease (STD), very common in the crowd that sexual behaviour is active.Although Genital warts can not cause serious consequence as cancer; but the clinical symptom that pathology can cause patient comparatively painful is usually as cusalgia, hemorrhage and pain; produce embarrassment, anxiety simultaneously and to feel oneself inferior etc. negative and psychoreaction, and the process of repeatedly treating wastes a large amount of medical resources.Worldwide estimate that the Genital warts caused by non-carcinogenic HPV (mainly 6 and 11 types) has 3,000 ten thousand, wherein 20 ~ 50% pathology in also include the polyinfection of high-risk HPV.3rd class: HPV infects can also cause recurrent respiratory papilloma (RRP), this be a kind of rare, there is potential fatefulue disease, mainly occur in adolescence, sometimes, a large amount of papillomas can cause has difficulty in breathing and causes less age death of child.
HPV is the double-stranded DNA virus without cyst membrane, primarily of virus coat and genomic dna composition (Bernard, Burketal.2011).HPV virus coat is by 360 L1 protein (forming 72 pentamers) and the icosahedral structure of virus that forms of 72 L2 protein at the most, diameter 55 ~ 60nm (HowleyandLowy2007).Virus capsid protein matter has self-assembly characteristic, L1 protein separately or form viral all particle (Virus-likeParticle with L2 protein co-assemble in vitro, VLP) (Chen, Garceaetal.2000, Finnen, Ericksonetal.2003, Buck, Chengetal.2008, WangandRoden2013).
Because HPV can not cell cultures in vitro, the specific antigens of this virus be obtained, recombinant vaccine can only be prepared by the method for recombinant DNA technology.The virus-like particle VLPs that restructuring Ll or L1/L2 assembling is formed, virus-free DNA, security is good, have with natural viral Particle Phase like epitope, neutralizing antibody IgG and IgA can be produced after stimulating body, therefore HPVVLPs can be used as preventative vaccine, thus greatly reduces the possibility (HowleyandLowy2007) causing producing related neoplasms because infecting HPV.
The key of HPV vaccine development to prepare high purity, stable HPV antigen in a large number.In HPV vaccine antigen technology of preparing, the expression system of production HPV antigen comparatively conventional at present can be divided into eukaryotic expression system and prokaryotic expression system.Conventional eukaryotic expression system has pox viruses express system, insect baculovirus expression system, yeast expression system.The formation VLP that HPVL1 energy expressed in eukaryotic expression system is spontaneous, often only need carry out simple purifying can obtain VLP.But because the expression amount of eukaryotic expression system is low, toxigenic capacity is high, brings extreme difficulties to large-scale industrial production.Utilize escherichia expression system to express HPVL1 protein in prokaryotic expression system to have been reported.But the HPVL1 protein solubility expressed by intestinal bacteria is low, purification process known at present obtains HPVVLP by the steps such as salt-free precipitation or sex change renaturation final purifying from the numerous and diverse enchylema of kinds of protein mostly.Such as: open by procaryotic cell expression and the polymeric method of preparation HPVL1 in patent CN02129070.9, wherein purifying process comprises by 3.3M Urea treatment and dialysis renaturation process; Also be by urea-denatured process to the purification process of L1-GST fused protein in WO-0204007 patent and carry out dialysis renaturation; Also there is open L1 protein purification method to be comprise phosphoric acid buffer ultrafiltration dialysis and centrifugal in the prior art, make target protein precipitate the step of redissolving again.But in these purge processes, protein losses amount is large, and yield is low, is difficult to apply in scale operation.
In the homogeneity of HPV vaccine antigen protein matter VLP, the grain size dispersity of the HPVL1VLP assembled in prior art has use polyd value to represent, polyd value <15% illustrates that particle has good homogeneity, illustrate between 15% to 30% that particle has larger unhomogeneity, be greater than 30% explanation particle homogeneous completely not.The HPVL1VLP prepared in prior art is much in 15%.Another illustrates that the index of uniform particle diameter is PdI value, and PdI value is size distribution coefficient, is less than 0.05 for highly homogeneous sample; 0.05 ~ 0.1 is as the criterion homogeneous sample, and 0.1 ~ 0.3 is the poor sample of homogeneity, is greater than 0.3 for inhomogenous sample.In US7205125B2 patent, the PdI of the mixed protein liquid of open HPV16-HPV18L1VLP is 0.07.
Therefore, this area still need that cost is low, purity is high, output is high, the novel method of stay-in-grade HPVL1 protein production technology and large-scale industrial production restructuring HPVL1VLP.
Summary of the invention
The object of the invention is the nucleotide sequence of the coding HPV16L1 protein of openly a kind of optimization, comprise the carrier of this nucleotide sequence, comprise the host cell of carrier, and by the HPVL1 protein of this polynucleotide sequence accurate translation, Tag-HPV-L1 recombinant protein, the pentamer formed by this L1 protein and VLP, and the vaccine infected as the prevention HPV that antigen forms by this pentamer and VLP.
first aspect present invention provides a kind of gene through codon optimized HPV16L1, its nucleotides sequence is classified as SEQNO:2.
second aspect present invention provides a kind of expression vector of structure,it comprises the gene through codon optimized HPV16L1 of first aspect present invention.Described carrier is applicable to driving allogeneic dna sequence DNA accurate translation HPVL1 protein in bacterium.In one embodiment, described expression vector preferred pGEX-6p-1, pGEX-4T-2, pMAL or pET28a.
a third aspect of the present invention provides a kind of engineering bacteria cell of structure,this cell comprises the gene of first aspect present invention, or the expression vector of second aspect.Described engineering bacteria host cell is intestinal bacteria, in one embodiment, and the preferred BL21 cell strain of described host cell.
fourth aspect present invention provides a kind of Tag-HPV16L1 fusion rotein,wherein label Tag is 6*His.Tag, GST.Tag, SUMO.Tag, MBP.Tag, 6*His-SUMO.Tag or GST-SUMO.Tag; L1 is that HPV16L1 full length protein and/or C hold brachymemma 5,10,15 or no more than 30 amino acid and/or N to hold brachymemma 2,4,6 or no more than 10 amino acid whose L1 protein.
The nucleotides sequence of coding Tag-HPVL1 fusion rotein GST-HPV16L1 is classified as SEQNO:3, SEQNO:11, the nucleotides sequence of GST-SUMO-HPV16L1 is classified as SEQNO:4, SEQNO:12, nucleotide sequence SEQNO:5, SEQNO:13 of MBP, the nucleotides sequence of 6*His-HPV16L1 is classified as SEQNO:6, and the nucleotides sequence of 6*His-SUMO-HPV16L1 is classified as SEQNO:7.
The aminoacid sequence SEQNO:10 of the aminoacid sequence of coding Tag-HPVL1 fusion rotein GST-HPV16L1 to be the aminoacid sequence of SEQNO:8, GST-SUMO-HPV16L1 be SEQNO:9, MBP.
the pentamer of the HPVL1 that fifth aspect present invention provides Tag-HPVL1 fused protein to obtain after purifying, and the VLP assembled by pentamer.hPV16L1 pentamer albumen median size 10 ~ 15nmPdI<0.1 in a preferred embodiment.Median size 45 ~ the 65nmPdI<0.1 of HPV16L1VLP in a preferred embodiment.
sixth aspect present invention provides a kind of vaccine composition,it comprises the pentamer of HPVL1 of the present invention or the VLP of HPVL1, comprises pharmaceutically useful vehicle and medicinal adjuvant further in described composition.
Absorption preparation will be carried out with aluminum hydroxide adjuvant normal saline solution according to albumen and aluminium content 1:10 ratio respectively containing HPV16L1 pentamer or VLP albumen stoste (preparing gained according to aforesaid method) in one embodiment and can obtain recombinate HPVL1 protein pentamer or VLP vaccine, stand-by 4 DEG C of preservations.
on the other hand, the present invention also provides a kind of method obtaining Tag-HPVL1 fusion rotein, comprises the steps:
A. by replacing the codon of the translation same protein of HPV16L1 gene order with the codon of intestinal bacteria preference, the gene of the codon optimized HPV16L1 of escherichia expression system preference is obtained;
B. the coli expression carrier of HPV16L1 gene is built;
C. the escherichia coli expression engineering strain of Tag-HPV16L1 is built;
D. abduction delivering purifying obtains fusion rotein Tag-HPV16L1.
Above-mentionedly prepare prokaryotic host cell in fusion rotein Tag-HPV16L1 method and be selected from but be not limited to GI698, ER2566, BL21 (DE3), XA90, B834 (DE3), BLR (DE3).
Above-mentionedly prepare expression condition in fusion rotein Tag-HPV16L1 method and be: under 20 ~ 37 DEG C of temperature condition, abduction delivering 3 ~ 20 hours.Preferred under 28 DEG C of temperature condition in a specific embodiment, abduction delivering 16 hours.
the present invention also provides a kind of method obtaining HPV16L1 pentamer, comprises the steps:
A) with affinity chromatography method absorption fusion rotein Tag-HPV16L1;
B) add proteolytic enzyme excision Tag label, obtain HPV16L1 pentamer protein;
C) purifying HPVL1 pentamer protein, obtain purity >98%, the L1 pentamer protein of median size 10 ~ 15nmPdI<0.1.
Be the site-specific proteolytic enzyme of excision Tag label for proteolytic enzyme described in above-mentioned preparation HPV16L1 pentamer method: restructuring HRV 3CP, zymoplasm, SUMO proteolytic enzyme, SENP1 or TEV protease.
In above-mentioned preparation HPV16L1 pentamer method, purification process is selected from but is not limited to ion exchange chromatography, hydrophobic chromatography method, molecular sieve (or claiming gel-filtration or size-exclusion) chromatography; Preferably purifying comprises ion exchange chromatography and molecular sieve chromatography.
In above-mentioned preparation HPV16L1 pentamer method, purification process also comprises use reductive agent, such as, add DTT.
HPV16L1 pentamer albumen median size 10 ~ 15nmPdI<0.1 is obtained after final purifying in above-mentioned preparation HPV16L1 pentamer method.
present invention also offers a kind of method that HPV16L1 pentamer is assembled into VLP, comprise the steps:
The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is mixed with assembling damping fluid, final acquisition pH value is 5.0 ~ 5.9, salt concn is 500 ~ 2000mM, the HPV16L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1, preferred acquisition pH value is 5.7, and salt concn is the HPV16L1VLP protein liquid of 1300mM.
Assembling damping fluid includes but not limited to Tris damping fluid, phosphate buffered saline buffer, acetate buffer solution, HEPES damping fluid, MOPS damping fluid, citrate buffer, histidine buffering liquid, borate buffer etc.
Above-mentioned HPV16L1 pentamer is assembled in the method for VLP can also add protective material in HPV16L1-VLP protein liquid, such as: 0.01 ~ 0.1 Polysorbate 80.
present invention also offers the method-cryogenic freezing process construction from part of another kind of assembling VLP, comprise the steps:
HPVL1 pentamer protein liquid is placed in pH value is 5.5 ~ 8.0 salt concn is damping fluid under 150 ~ 1000mM condition, completely freezing under-20 ~-80 DEG C of conditions, preferably after freezing 24 hours, place room temperature again to melt to protein stoste, obtain the HPV16L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.
on the other hand, present invention also offers the pentamer of HPVL1, VLP and comprise the vaccine of pentamer or VLPthe application of composition in the medicine of preparation prevention HPV infection.
According to the present invention, vaccine of the present invention can adopt the acceptable form of patient, includes but not limited to that injection or nasal cavity or oral cavity suck or vagina administration, optimizing injection and intramuscularly.
the explanation of relational language and explanation in the present invention
According to the present invention, term " escherichia expression system " refers to and is made up of intestinal bacteria (bacterial strain) and carrier, wherein intestinal bacteria (bacterial strain) derive from available on the market, illustrate at this but be not limited to: GI698, ER2566, BL21 (DE3), XA90, DH (5a), B834 (DE3), BLR (DE3).
According to the present invention, term " carrier " word refers to and the polynucleotide of certain coded protein can be inserted wherein and make protein obtain a kind of nucleic acid launch vehicle of expressing.Carrier can by transforming, and transduction or transfection host cell, the genetic material element making it carry obtains expression in host cell.For example, carrier comprises: plasmid; Phage; Coemid etc.
According to the present invention, " vaccine vehicle or carrier " refer to and are selected from one or more, include but not limited to: pH adjusting agent, tensio-active agent, adjuvant, ionic strength toughener term.Such as, pH adjusting agent is illustrated but is not limited to phosphate buffered saline buffer, and tensio-active agent comprises positively charged ion, negatively charged ion or nonionic surface active agent.Illustrate but be not limited to: Polysorbate 80.Adjuvant is illustrated but is not limited to aluminium hydroxide, aluminum phosphate, Fu Shi Freund's complete adjuvant, Fu Shi Freund's incomplete adjuvant etc.Ionic strength toughener is illustrated but is not limited to sodium-chlor.
According to the present invention, term " chromatogram " includes but not limited to: ion-exchange chromatography (such as cation-exchange chromatography, anion-exchange chromatography), hydrophobic interaction chromatograph, adsorption chromatography chromatography (such as hydroxylapatite chromatography), molecular sieve chromatography chromatography (gel-filtration or molecular exclusion chromatography), affinity chromatography method.
According to the present invention, in the restructuring HPVL1 method of protein that the present invention obtains, damping fluid refers to a kind of solution that greatly can reduce pH amplitude of fluctuation when adding a small amount of acid or alkali and water, include but not limited to Tris damping fluid, phosphate buffered saline buffer, acetate buffer solution, HEPES damping fluid, MOPS damping fluid, citrate buffer, histidine buffering liquid, borate buffer etc.
According to the present invention, described cytoclasis include but not limited to broken by homogenizer, clarifixator is broken, ultrasonication, grinding, high-pressure extrusion, in N,O-Diacetylmuramidase process one or multinomial method realize;
According to the present invention, in the restructuring HPVL1 method of protein that the present invention obtains, salt used includes but not limited to it is neutral salt, particularly an alkali metal salt, ammonium salt, hydrochloride, vitriol, supercarbonate, one or more in phosphoric acid salt or hydrophosphate, particularly NaCI, KCl, CaCl2, NH4Cl, KCI, NH4CI, MgSO4, (NH4) 2SO4.Preferred NaCI.Reductive agent used includes but not limited to DTT, 2 mercapto ethanol.Amount used includes but not limited to 2mM ~ lO0mM, preferably 10 ~ 15mM.
Beneficial effect
The invention provides a kind of synthetic gene, this gene order carried out codon optimized nucleotide sequence according to colibacillary codon preference, this sequence encoding HPVL1 protein amino acid sequence.Research finds that the nucleotide sequence of codon optimization is significantly increased relative to the expression amount of the L1 albumen without codon optimized nucleotide sequence.
Escherichia expression system disclosed by the invention have expression amount high, be easy to cultivate and operation and the advantage such as production cost is low.But only use this expression system to be still difficult to directly obtain the HPVL1 albumen of great amount of soluble, its reason is the as easy as rolling off a log formation inclusion body of L1 albumen, i.e. the insoluble polymer of abiology activity.In addition, even if obtain a large amount of inclusion bodys, in order to obtain the albumen of biologic activity, also sex change, renaturation process must be carried out to inclusion body, the albumen of this process often large losses.In order to solve this difficult problem, the present invention adopts integration technology, by L1 gene with have assist protein correctly to fold albumen as glutathione S-transferase (GST), SUMO, MBP, 6*His-SUMO or GST-SUMO etc. carry out amalgamation and expression, not only the solubility of albumen and yield increase, and GST-SUMO-HPVL1, 6*His-SUMO-HPVL1 makes do not have the residual of exogenous amino acid at HPVL1 protein N terminal, find the fusion tag that GST-SUMO wherein expresses as recombinant protein HPVL1 and molecular chaperones simultaneously, there is protease inhibitor hydrolysis, remarkable increase expression of recombinant proteins amount and promotion target protein correctly fold, improve the functions such as solubility.Therefore the technological line that the present invention adopts have employed label protein integration technology when building HPVL1 protein expression vector, the fusion rotein formed by label protein and L1 albumen on the one hand improves the solubility of target protein, improve output, affinity chromatography and proteolytic ferment excision can be utilized to merge the purifying feature that matter stamp methods carries out target protein by GST fusion tag on the other hand, thus achieve single step purification from the cell pyrolysis liquid of broad categories and can obtain the HPVL1 albumen that purity reaches more than 70%, substantially increase purification efficiency, thus improve the output of end product HPVL1 albumen.
Provided by the inventionly first to express, separation and purification to obtain after highly purified HPVL1 pentamer albumen Artificial Control assembling again and form the technological line of VLP, can solve current known technology exist from foreign protein miscellaneous cytoclasis liquid, direct purification VLP purity is low, degraded ratio is high, the problem that yield is low, obtains high purity pentamer assembled in vitro VLP and VLP preservation condition.
In addition, the present inventor have been surprisingly found that a kind of new assembling condition and method: i.e. cryogenic freezing process construction from part.The VLP obtained by the method inhomogenous for the particle diameter assembled before freeze thawing protein (PdI is greater than 0.1) can be become size coincidence theory expection and also homogeneous, the VLP that PdI is less than 0.1, the VLP that contrast prior art obtains is more stable, and different salt concn, pH value range can be stored in widely in damping fluid, the dilution of final vaccine preparation of being more convenient for and preparation.
The present invention, through the HPVL1VLP protein of gained of recombinating, has good immunogenicity, can the neutralizing antibody for homotype HPV of induced high titers, and HPV is to the infection of human body in prevention, is a kind of good vaccine form.
With reference to as detailed below and
accompanying drawingafter, these and other aspect of the present invention will be obvious.All reference disclosed herein all completely to be quoted as a reference at this.
Accompanying drawing explanation
Fig. 1: GST-HPV16L1 protein is affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is protein mass marker Lane: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kdat, and left swimming lane is the resin of affine absorption GST-L1, and right swimming lane is the resin of GST and L1 after enzymolysis.
Fig. 2: GST-SUMO-HPV16L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption GST-SUMO-L1, and right swimming lane is the resin of GST-SUMO and L1 after enzymolysis.
Fig. 3: MBP-HPV16L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption MBP-L1, and right swimming lane is the resin of MBP and L1 after enzymolysis.
Fig. 4: 6*HIS-SUMO-HPV16L1 protein through affine with enzymolysis after SDS-PAGE gel electrophoresis figure.M swimming lane is for being protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and left swimming lane is the resin of affine absorption 6*HIS-SUMO-L1, and right swimming lane is the resin of 6*HIS-SUMO and L1 after enzymolysis.The fused albumen with 6*HIS-SUMO label is not cut by gel electrophoresis figure display proteolytic enzyme.
Fig. 5: the restructuring HPV16L1 pentamer protein s DS-PAGE gel electrophoresis figure of the present invention after molecular sieve chromatography purifying.M swimming lane is protein mass standard (being from top to bottom: 94kDa, 66kDa, 45kDa, 33kDa, 26kDa, 20kda), and another swimming lane is HPVL1 albumen.
The dynamic light scattering observed result of Fig. 6: HPV16L1 pentamer.The particle size diameter of result display pentamer is 12.62nM, size-grade distribution PdI is 0.030.
The dynamic light scattering observed result of Fig. 7: HPV16L1VLP.The particle size diameter of result display VLP is 47.79nM, size-grade distribution PdI is 0.019.
The transmission electron microscope photo of Fig. 8: HPV16L1 pentamer albumen.
The transmission electron microscope photo of Fig. 9: HPV16L1VLP albumen.
The high-pressure liquid phase molecular sieve chromatography figure of Figure 10: HPV16L1 pentamer protein, shows in figure and is greater than 98% through highly purified L1 pentamer lipidated protein.
The high-pressure liquid phase molecular sieve chromatography figure of Figure 11: HPV16L1VLP protein, shows in figure and is greater than 98% through highly purified VLP lipidated protein.
After Figure 12: HPV16L1 pentamer and each experimental group vaccinated mice of HPV6L1VLP, at second time booster immunization after 4 weeks, detect the average titer level of neutralizing antibody.
Below in conjunction with embodiment, the present invention is illustrated description further.These embodiments are nonrestrictive.
EXAMPLE l: the Design and synthesis of codon optimized HPVL1 gene
Gene order derives from published various HPV sequence on PUBMED.With reference to intestinal bacteria, to selected various HPVDNA sequence, all HPVDNA sequences of codon optimized rear synthesis are carried out to the preference of genetic transcription codon.According to synthetic DNA primers, synthetic gene is utilized to carry out pcr amplification for template.The codon optimised sequence of gained is verified by determined dna sequence.
The various DNA sequence dna of HPV before optimizing and after optimizing:
SEQNO.1: the DNA sequence dna of the HPV16 type L1 before optimization
SEQNO.2: the DNA sequence dna of the HPV16 type L1 after optimization
Embodiment 2: the structure of recombinant vectors pGEX-6P-1-GST-HPV16L1 and qualification:
The DNA fragmentation primer of amplification HPV16L1: (restriction enzyme site is BamHI and XhoI respectively)
Forward-HPV16L1-ApaI:5’ACTTCA
GGATCCATGTCTCTGTGGCTGCCGTCTG
Reverse-HPV16L1-XhoI:5’ATCTCA
CTCGAGCTACAGTTTACGCTGTTTACGTTT
pcr amplification reaction system:10xPfubuffer20 μ L, Pfu enzyme 4 μ L, 10mMdNTP2.5 μ L, 5 ' Primer (5 μMs) 10 μ L, 3 ' Primer (5 μMs) 10 μ L, template DNA 50ng, adds d2H2O to 200 μ L.
gene PCR amplification condition:95 DEG C of 3min; 95 DEG C of 30sec, 58 DEG C of 30sec, 72 DEG C of 4min; Circulate 32 times; 72 DEG C of 10min.
L1 gene fragment containing BamHI and XhoI restriction enzyme site and vector pGEX-6P-1 are carried out the process of BamHI/XhoI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGEX-6P-1 containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order afterwards by Shanghai Sheng Gong biotech firm, the nucleotides sequence obtaining merging restructuring GST-HPV16-L1 protein is classified as SEQNO.3, and aminoacid sequence is SEQNO.8.
With reference to the fusion recombinant vectors GST-HPV-L1 of this embodiment method preparation with GST label, its gene order SEQNO.11.
Embodiment 3: recombinant vectors pGEX-6P-1m-GST-SUMO-HPV16L1 vector construction
PGEX-6p-1m vector construction: the unique ApaI restriction enzyme site being carrier for the ApaI restriction enzyme site (GGGCCC) making multienzyme cut location proximate, under the prerequisite not changing lacI gene protein expressed sequence, by the synonym GGT that the Gly codon GGC in another ApaI recognition sequence GGGCCC of commercially available pGEX-6p-1 carrier is changed into it by point mutation technology, ApaI(3890 can be eliminated).ApaI is become can be used to the site of inserting expressing gene by such transformation.
The DNA fragmentation primer of amplification SUMO: (restriction enzyme site is ApaI and BamHI respectively)
Forward-SUMO-ApaI:ACTTCA
GGGCCCTCTGACCAGGAAGCTAAACCGTC
Reverse-SUMO-BamHI:CGC
GGATCCACCGGTCTGTTCCTGGTAAAC
The DNA fragmentation primer of amplification HPV16L1: (restriction enzyme site is BamHI and XhoI respectively)
Forward-HPV16L1-ApaI:5’ACTTCA
GGATCCATGTCTCTGTGGCTGCCGTCTG
Reverse-HPV16L1-XhoI:5’ATCTCA
CTCGAGCTACAGTTTACGCTGTTTACGTTT
pcr amplification reaction system:10xPfubuffer20 μ L, Pfu enzyme 4 μ L, 10mMdNTP2.5 μ L, 5 ' Primer (5 μMs) 10 μ L, 3 ' Primer (5 μMs) 10 μ L, template DNA 50ng, adds d2H2O to 200 μ L.
gene PCR amplification condition:95 DEG C of 1.5min; 95 DEG C of 30sec, 58 DEG C of 30sec, 72 DEG C of 1min; Circulate 32 times; 72 DEG C of 10min.
the same above-described embodiment of gene PCR amplification condition.
Enzyme cuts connection: the SUMO gene fragment containing ApaI and BamHI restriction enzyme site and vector pGEX-6P-1m are carried out the process of ApaI/BamHI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGEX-6P-1m containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
Transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtaining merging recombinant vectors pGSTSUMO-6p-1m.
Enzyme cuts connection again: the L1 gene fragment containing BamHI and Xho1 restriction enzyme site and recombinant vectors pGSTSUMO-6p-1m are carried out the process of BamHI/Xho1 double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pGSTSUMO-6p1m containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
Again transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening is carried out enlarged culturing and carries out the extraction of plasmid, checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtain the fusion recombinant vectors GST-SUMO-L1 with GST-SUMO label, its gene order SEQNO.4, aminoacid sequence is SEQNO.9.
With reference to the fusion recombinant vectors GST-SUMO-L1 of this embodiment method preparation with GST label, its gene order SEQNO.12.
Embodiment 4: the structure of recombinant vectors pMAL-MBP-HPV16L1
The DNA fragmentation primer of amplification HPV16L1: (restriction enzyme site is EcoRI and HindIII respectively)
Forward-HPV16L1-EcoRI:5’ACTTCA
GAATTCATGTCTCTGTGGCTGCCGTCTG
Reverse-HPV16L1-HindIII:5’ATCTCA
AAGCTTCTACAGTTTACGCTGTTTACGTTT
L1 gene fragment containing EcoRI and HindIII restriction enzyme site and carrier pMAL are carried out the process of EcoRI/HindIII double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pMAL containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order afterwards by Shanghai Sheng Gong biotech firm, obtain the gene order SEQNO.5 merging restructuring MBP-HPV16-L1 protein, aminoacid sequence is SEQNO.10.
With reference to the fusion recombinant vectors MBP-HPV-L1 of this embodiment method preparation with MBP label, its gene order SEQNO.13.
Embodiment 5: the structure of recombinant vectors pET28a-6*His-HPV16L1
The DNA fragmentation primer of amplification HPV16L1: (restriction enzyme site is NdeI and XhoI, pET28a respectively)
Forward-HPV16L1-NdeI:5’GACTTCA
CATATGATGTCTCTGTGGCTGCCGTCTG
Reverse-HPV16L1-XhoI:5’CATCTCA
CTCGAGCTACAGTTTACGCTGTTTACGTTT
L1 gene fragment containing NdeI and XhoI restriction enzyme site and carrier pMAL are carried out the process of NdeI/XhoI double digestion, utilizes T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pET28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
The screening connecting and carry out recon in product to Host Strains DH5 α is transformed after ligation.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Shanghai Sheng Gong biotech firm afterwards, obtaining the gene order SEQNO.6 merging restructuring MBP-HPV16-L1 protein.
Embodiment 6: recombinant vectors 6*His-SUMO-HPV16L1 vector construction
The DNA fragmentation primer of amplification SUMO: (restriction enzyme site is NdeI and BamHI respectively)
Forward-SUMO-NdeI:GGAATTC
CATATGTCTGACCAGGAAGCTAAACCGTC
Reverse-SUMO-BamHI:CGC
GGATCCACCGGTCTGTTCCTGGTAAAC
The DNA fragmentation primer of amplification HPV16L1: (restriction enzyme site is BamHI and XhoI respectively)
Forward-HPV16L1-ApaI:5’ACTTCA
GGATCCATGTCTCTGTGGCTGCCGTCTG
Reverse-HPV16L1-XhoI:5’ATCTCA
CTCGAGCTACAGTTTACGCTGTTTACGTTT
SUMO gene, L1
gene PCR amplification condition, reaction system are with described in above-described embodiment.
Enzyme cuts connection: the SUMO gene fragment containing NdeI and BamHI restriction enzyme site and carrier pET-28a are carried out the process of NdeI/BamHI double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pET28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
Transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Jin Weizhi bio tech ltd, Suzhou afterwards, obtaining merging recombinant vectors pETSUMO-28a.
Enzyme cuts connection again: the L1 gene fragment containing BamHI and Xho1 restriction enzyme site and recombinant vectors pETSUMO-28a are carried out the process of BamHI/Xho1 double digestion, utilize T4DNA ligase enzyme that the gene fragment of recovery is carried out ligation with the pETSUMO-28a containing corresponding sticky end afterwards, 16 DEG C of 10 ~ 15h.
Again transform qualification: after ligation, transform the screening connecting and carry out recon in product to Host Strains DH5 α.The mono-clonal bacterium colony of screening carried out enlarged culturing and carries out the extraction of plasmid, being checked order by Shanghai Sheng Gong biotech firm afterwards, obtaining the gene order SEQNO.7 merging restructuring MBP-HPV16-L1 protein.
Embodiment 7: restructuring HPVL1 pentamer protein expression
By the recombinant vectors transformation of E. coli BL21 host cell of correct for sequencing result embodiment 2,3,4,5 and 6, and carry out the expression of HPVL1 albumen as the engineering bacteria of expressing recombinant protein.Recombinant base is 2YT substratum (10g/L tryptone; 5g/L yeast powder; 10g/LNaCl).Picking contains the thalline list spot of recombinant plasmid in 10ml2YT substratum (containing 100 μ g/ml penbritins), and 230 revs/min (rpm), 37 DEG C of shaking culture are spent the night.Switching 5ml spends the night bacterium in 500ml(containing 100 μ g/ml penbritins) in 2YT liquid nutrient medium, 37 DEG C of concussions are cultured to recombinant bacterial strain when growing to OD600nm ≈ 0.4 ~ 1, add the IPTG induction of final concentration 0.2mM, under the condition of 28 DEG C, carry out the abduction delivering of more than 6h recombinant protein.
Cell harvesting and fragmentation
:carry out centrifugal to fermenting culture, abandon supernatant, results bacterial sediment, weighs; Use bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) washing precipitation, is then resuspended in bufferL and is carried out ultrasonic disruption, carries out centrifugal (16000rpm subsequently by supercentrifuge to broken bacterium liquid, 30min, 4 DEG C), collect supernatant liquor.
Embodiment 8: restructuring HPVL1 pentamer albumen is in the detection of expression in escherichia coli amount
Before adopting ELISA sandwich assay to detect affinity chromatography loading, Tag-HPVL1 pentamer albumen is in expression in escherichia coli amount, sample and trial-product:
coated antibody:make anti-HPV16L1 mouse monoclonal by oneself.
reference substance:make highly purified HPV16L1 albumen by oneself.
trial-product:with sample diluting liquid by trial-product
tag-HPV16L1be diluted to concentration in reference substance gradient dilution concentration range.
enzyme labelled antibody:the anti-HPV16L1 albumen of rabbit of homemade horseradish peroxidase-labeled resists more.
result calculates:calculate the mean value of parallel hole, with reference substance series concentration OD
450absorption value makes straight-line equation to its corresponding L1 proteantigen, and between Duplicate Samples sample wells, the variation coefficient must not be greater than 10%, linear regression equation R
2must not 0.980 be less than, by the OD of trial-product
450absorption value substitutes into Equation for Calculating and goes out trial-product L1 proteantigen content after dilution, then is multiplied by corresponding extension rate and is L1 proteantigen content in trial-product, in table 1.
Tag-HPVL1 proteantigen content after table 1 detects and expresses
Embodiment 9: restructuring HPVL1 pentamer protein affinity chromatography
affinity chromatography with GST label recombinant protein:gST agarose affinity chromatography medium 5ml is loaded in affinity column, with bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) balance chromatography column, then in loading embodiment 8 with the protein liquid of GST or GST-SUMO label, after with BufferL be washed till without protein flow out, affine complete.With 5mLBufferL suspension affinity media, sampling detects and in conjunction with the total amount of L1 protein in calculation medium.
affinity chromatography with MBP label recombinant protein:amylose-Resin affinity chromatography medium 5ml is loaded in affinity column, with bufferL(pH8.0,50mMTris, 200mMNaCl, 5mMDTT) balance chromatography column, then in loading embodiment 8 with the protein liquid of GST or GST-SUMO label, after with BufferL be washed till without protein flow out, affine complete.With 5mLBufferL suspension affinity media, sampling detects and in conjunction with the total amount of L1 protein in calculation medium.
affinity chromatography with 6*HIS label recombinant protein:get 5mlNi-NTA gel dress post, post slowly adds the balance liquid (50mmol/LNaH2PO4,300mmol/LNacl, 20mmol/Limidazole adjust pH value to 8 with NaOH) of 10 times of column volumes, and fully to balance Ni-NTA gel, flow velocity is 1ml/min.The supernatant liquor with 6*His label after filtering in Example 8, after entering gel completely, continue detergent gel with the balance liquid of 10 times of column volumes, preservation flow velocity is 1ml/min.Be eluted to balance liquid and flow out without protein, affine complete.Sampling detects and in conjunction with the total amount of L1 protein in calculation medium.
Embodiment 10: the enzyme of restructuring Tag-HPVL1 protein cuts purifying
Enzyme amount is added according to target protein matter and proteolytic enzyme mass ratio 100:1, protein HRV 3CP wherein with GST-HPV-L1 is cut, protein with GST-SUMO-HPV-L1 and 6*His-SUMO-HPV-L1 SENP1 proteolytic cleavage, protein with Mbp-HPV-L1 FactorXa proteolytic cleavage, protein with 6*His-HPV-L1 Thrombin proteolytic cleavage, respectively after Double digestion 2h, wash-out collects the HPV16L1 pentamer protein soln of gained after each proteolytic cleavage respectively.
3C enzyme enzyme is cut the L1 protein soln SDS-PAGE detected through gel electrophoresis after GST label, the results are shown in Figure 1 affinity chromatography electrophoresis result, experiment shows, the target protein of 90% can be cut.Fig. 2 is the protein of SENP1 proteolytic cleavage with GST-SUMO-HPV-L1, uses SDS-PAGE detected through gel electrophoresis.Fig. 3 is the protein of FactorXa proteolytic cleavage with Mbp-HPV-L1, uses SDS-PAGE detected through gel electrophoresis.Fig. 1-Fig. 3 obtains the HPV16L1 albumen of 55kDa.
Thrombin proteolytic enzyme does not cut the protein of 6*His-HPV-L1; Cut the protein soln SDS-PAGE detected through gel electrophoresis of 6*His-SUMO-L1 with SENP1 enzyme, the results are shown in Figure 4, display SENP1 proteolytic enzyme fails to cut the fused albumen with 6*His-SUMO label.
Embodiment 11: restructuring HPVL1 pentamer protein purification
Molecular sieve chromatography purifying: the enzyme that a upper embodiment is collected is cut the HPV16L1 pentamer protein after purifying and carries out purifying respectively, can first through the HPV16L1 pentamer protein of ion-exchange chromatography collection, or directly use the gel filter medium of Superdex200 (production of GE company) to carry out further sieve chromatography without ion-exchange step, molecular sieve moving phase is pH8.0,10mMTris, 100mMNaCl, collects the cut of HPV16L1 pentamer protein ultraviolet absorption peak.
Working sample purity after purifying: SDS-PAGE detected through gel electrophoresis is used in the protein soln collected sampling, target protein matter HPV16L1 pentamer final purity after sieve chromatography purifying is all greater than 98%, refer to Fig. 5, the restructuring HPV16L1 pentamer protein s DS-PAGE gel electrophoresis figure after molecular sieve chromatography purifying.
Working sample protein concentration: carry out protein concentration detection by Bradford method, standard specimen 2mg/mlBAS preparation is used to be diluted to 500ug/ul from 100ug/ul, example reaction system gets the BSA+200ulBradford working fluid of 10ul dilution: typical curve is y=0.0013x-0.0294, R2=0.9986, the OD of working sample
595, substitute into typical curve, the protein concentration of calculation sample, the results are shown in Table 2.
Table 2Bradford method detects restructuring HPV16L1 pentamer protein concentration
Note: sample sets 1 is that GST-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification; Sample sets 2 is that GST-SUMO-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification; Sample sets 3 is that Mbp-HPVL1 obtains HPVL1 pentamer protein solution after molecular sieve purification.
Embodiment 12: restructuring HPV16L1 pentamer protein group dresses up VLP
Be placed under following salt concn (NaCl) and pH value condition, HPVL1 pentamer solution example group 1,2 and 3, place after stablizing, use the dynamic light scattering particle instrument of Malvern ZetasizerNanoZS, (size distribution FACTOR P dI value is grain size dispersity index, is less than 0.05 for highly homogeneous sample to carry out particle diameter and particle size distribution measuring; 0.05 ~ 0.1 is as the criterion homogeneous sample, and 0.1 ~ 0.3 is the poor sample of homogeneity, is greater than 0.3 for inhomogenous sample), the assembling of HPV16L1 pentamer albumen obtains the VLP(of uniform particle diameter
pdI < 0.05).
The droplet measurement of HPV16L1VLP is assembled under the different pH of table 3 and salt concentration conditions
Note: sample sets 1 is that GST-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification; Sample sets 2 is that GST-SUMO-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification; Sample sets 3 is that Mbp-HPVL1 obtains HPVL1VLP protein solution after molecular sieve purification.
Embodiment 13: dynamic light scattering (DLS) is to L1 pentamer and VLP protein particle size determination
Instrument is the dynamic light scattering particle instrument of Malvern ZetasizerNanoZS, get HPV16L1 pentamer that each sample group finally obtains and HPV16L1VLP protein detects, survey the homogeneity that median size and monodispersity index PdI(show protein), illustrate the L1 pentamer that each group of sample is finally prepared and VLP albumen homogeneous.The pentamer protein that wherein sample sets 2 is finally obtained and the HPV16L1VLP protein size distribution that its assembling obtains refer to
accompanying drawing 6 He7.
The preparation of embodiment 14:HPV16L1 pentamer and VLP
According to the technology that the above embodiment of the present invention 1-13 adopts, preparation has sequence 11,12, the HPV16L1 albumen of 13, above albumen all can obtain the albumen that purity reaches more than 98% by purifying, obtains the HPV16L1 pentamer albumen of median size 10 ~ 15nmPdI<0.1.Further assembling obtains the HPV16L1VLP albumen of median size 45 ~ 65nmPdI<0.1.
Embodiment 15: cryogenic freezing process is tested the impact of L1 pentamer albumen assembled in vitro VLP
At room temperature L1 pentamer albumen is placed in salt concn and the pH value condition assembling VLP of following table, and surveys its particle diameter and PdI value.To place it under-80 DEG C of conditions freezing treatment subsequently 24 hours, and then place room temperature and melt to protein soln, again detect its particle diameter and PdI value.Through freezing treatment the inhomogenous protein of particle diameter (PdI is greater than 0.1) that (before freeze thawing) assembles at ambient temperature can be become size coincidence theory expection and also homogeneous, the VLP albumen that PdI is less than 0.1.
Table 4HPV16L pentamer albumen at room temperature assembles the droplet measurement result of VLP
The droplet measurement result of VLP is assembled after table 5HPV16L pentamer albumen-80 DEG C of freezing treatment
The morphologic detection of embodiment 16:HPV16L1 pentamer and VLP
transmission electron microscope observing:the HPV16L1-VLP protein that the HPV16L1 pentamer protein obtained by each purifying in embodiment, assembling obtain, utilizes transmission electron microscope platform to observe by Instite of Biophysics, Chinese Academy of Sciences.Freezing sample preparation and flow process of taking pictures:
1) by liquid nitrogen box filled with liquid nitrogen, when liquid level does not seethe with excitement, ethane is slowly injected the copper bowl of cooling, make it to be cooled to liquid state.
2) copper mesh is done wetting ability process at PDC-32 type plasma cleaning device.
3) in the freezing sample preparation device of VitrobotTMMarkIV, by the pentamer of 3.5 μ L and VLP sample adsorption in 300 object QUANTIFOIL copper mesh, after water suction 4s, by the freezing sample of liquid ethane.
4) rapid being transferred in liquid nitrogen by sample is preserved.
5), when collecting freezing photo, electron dose is 20e-/2.Data are by the GatanUltraScan4000CCD record of the 300kVTitanKrios transmission electron microscope of 300KV.Acceleration voltage is 300kV.
Result shows, in HPV16L1 pentamer protein example group, and the pentamer albumen of about the 10nm that visible a large amount of diameter conforms to theoretical size in the visual field; In HPV16L1-VLP protein example group, a large amount of diameters that visible particle size conforms to theory are the virus-like particle (VLP) of about 50nm, uniformity.After wherein GST-SUMO set of tags (sample sets 2) enzyme cuts purifying, the transmission electron microscope photo of HPV16L1 pentamer gained sample is shown in
accompanying drawingthe transmission electron microscope photo of the VLP albumen that 8, Mbp set of tags (sample sets 3) enzyme is assembled after cutting purifying is again shown in
accompanying drawing9.
Embodiment 17:HPV16L1 protein stoste purity detecting
Size Exclusion High Performance liquid chromatogram measuring: chromatographic column AgilentBioSEC-5um, 2000,7.8 × 300mm, column volume is about 15m1, molecular weight ranges >=lO, OOOkDa; With the 0.1mol/L phosphate buffered saline buffer of pH6.8 (take Sodium phosphate dibasic 25.8g, SODIUM PHOSPHATE, MONOBASIC 4.37g, add ultrapure water and make dissolving, with phosphoric acid adjust pH to 6.8, ultrapure water constant volume becomes 1000ml) be moving phase; Flow velocity is 1ml/min; Determined wavelength 280nm; Column temperature 25 DEG C, applied sample amount must not be less than 20ug, and sample main peak theoretical plate number is not less than 1000, and tailing factor is less than 2.0, continuous sample introduction 5 pin, and the relative standard deviation of peak area must not be greater than 3%.
Get the 2 groups of HPV16L1 finally obtained of the sample after purifying
pentamerwith assembling after
vLPprotein stoste, weaker concn is 1mg/ml respectively, and applied sample amount 20ul injects high pressure liquid chromatograph, detects according to the method described above, and by area normalization method calculated purity, all process lipidated proteins are all greater than 98%, the results are shown in
accompanying drawing10 and table 6,
accompanying drawing11 and table 7.
The HPLC lipidated protein of table 6HPV16L1 pentamer detects
After table 7HPV16L1 assembling
vLPhPLC lipidated protein detect
| Peak | Retention time | Area | Area % |
| 1 | 13.854 | 2673380 | 100.00 |
| Amount to | 2673380 | 100.00 |
Embodiment 18:HPVVLP stability experiment
The HPV16VLP protein each sample sets finally obtained, under the buffer conditions of following table, is placed 14 days to 28 days at 25 DEG C, is carried out droplet measurement, the results are shown in following table, prove that HPV16VLP is at pH5.0 to 5.9, deposit stable under salt concn 500 ~ 2000mM.Sample sets 3 gained HPV16VLP is at pH5.0 to 5.9, and after placing 14-28 days under salt concn 500 ~ 2000mM, detected result refers to as following table.
Table 8HPV16L1VLP places 14-28 days droplet measurement results at 25 DEG C
Embodiment 19: preparation contains the univalent vaccine of HPVL1 pentamer or VLP
HPV16L1 pentamer containing each sample sets or VLP albumen stoste are carried out absorption preparation with aluminum hydroxide adjuvant normal saline solution according to albumen and aluminium content 1:10 ratio respectively and can obtain recombinate HPVL1 protein pentamer or VLP vaccine, stand-by 4 DEG C of preservations.
The immunogenicity determining of embodiment 20:HPVL1 pentamer and VLP
Get above-mentioned L1 pentamer or VLP vaccine respectively, the physiological saline adding sterilizing is diluted to pentamer or the VLP protein vaccine of 20 μ g/ml concentration respectively, with every 0.1ml intramuscular injection BALB/c mouse, often organizes 10.Mouse every 4 weeks booster immunizations once, are total to immunity 2 times.Booster immunization is after 4 weeks, and for the NAT of homotype HPV in the mice serum after adopting pseudovirus cell Neutralizing test method to measure each immunity respectively, result is as attached
figureshown in 12.
Result shows, HPVL1 pentamer and VLP protein vaccination mouse, after second immunisation, 4 weeks neutralizing antibodies can reach very high level.The results show, the VLP vaccine of HPVL1 pentamer and assembling all can produce neutralizing antibody in animal body, illustrate that HPVL1 pentamer and VLP protein vaccine all have immunogenicity in human clinical trial, the disease that HPV homologous virus causes can be prevented.
SEQUENCELISTING
<110> Beijing Health Guard Biotechnology Co., Ltd.
<120>16 type recombinant human papilloma virus virus-like particle and preparation method thereof
<130>2014
<160>13
<170>PatentInversion3.3
<210>1
<211>1518
<212>DNA
<213> artificial sequence
<400>1
atgtctctttggctgcctagtgaggccactgtctacttgcctcctgtcccagtatctaag60
gttgtaagcacggatgaatatgttgcacgcacaaacatatattatcatgcaggaacatcc120
agactacttgcagttggacatccctattttcctattaaaaaacctaacaataacaaaata180
ttagttcctaaagtatcaggattacaatacagggtatttagaatacatttacctgacccc240
aataagtttggttttcctgacacctcattttataatccagatacacagcggctggtttgg300
gcctgtgtaggtgttgaggtaggtcgtggtcagccattaggtgtgggcattagtggccat360
cctttattaaataaattggatgacacagaaaatgctagtgcttatgcagcaaatgcaggt420
gtggataatagagaatgtatatctatggattacaaacaaacacaattgtgtttaattggt480
tgcaaaccacctataggggaacactggggcaaaggatccccatgtaccaatgttgcagta540
aatccaggtgattgtccaccattagagttaataaacacagttattcaggatggtgatatg600
gttgatactggctttggtgctatggactttactacattacaggctaacaaaagtgaagtt660
ccactggatatttgtacatctatttgcaaatatccagattatattaaaatggtgtcagaa720
ccatatggcgacagcttatttttttatttacgaagggaacaaatgtttgttagacattta780
tttaatagggctggtgctgttggtgaaaatgtaccagacgatttatacattaaaggctct840
gggtctactgcaaatttagccagttcaaattattttcctacacctagtggttctatggtt900
acctctgatgcccaaatattcaataaaccttattggttacaacgagcacagggccacaat960
aatggcatttgttggggtaaccaactatttgttactgttgttgatactacacgcagtaca1020
aatatgtctttatgtgctgccatatctacttcagaaactacatataaaaatactaacttt1080
aaggagtacctacgacatggggaggaatatgatttacagtttatttttcaactgtgcaaa1140
ataaccttaactgcagacgttatgacatacatacattctatgaattctactattttggag1200
gactggaattttggtctacaacctcccccaggaggcacactagaagatacttataggttt1260
gtaacatcccaggcaattgcttgtcaaaaacatacacctccagcacctaaagaagatccc1320
cttaaaaaatacactttttgggaagtaaatttaaaggaaaagttttctgcagacctagat1380
cagtttcctttaggacgcaaatttttactacaagcaggattgaaggccaaaccaaaattt1440
acattaggaaaacgaaaagctacacccaccacctcatctacctctacaactgctaaacgc1500
aaacaacgtaagctgtaa1518
<210>2
<211>1515
<212>DNA
<213> artificial sequence
<400>2
atgtctctgtggctgccgtctgaagctaccgtttacctgccgccggttccggtttctaaa60
gttgtttctaccgacgaatacgttgctcgtaccaacatctactaccacgctggtacctct120
cgtctgctggctgttggtcacccgtacttcccgatcaaaaaaccgaacaacaacaaaatc180
ctggttccgaaagtttctggtctgcagtaccgtgttttccgtatccacctgccggacccg240
aacaaattcggtttcccggacacctctttctacaacccggacacccagcgtctggtttgg300
gcttgcgttggtgttgaagttggtcgtggtcagccgctgggtgttggtatctctggtcac360
ccgctgctgaacaaactggacgacaccgaaaacgcttctgcttacgctgctaacgctggt420
gttgacaaccgtgaatgcatctctatggactacaaacagacccagctgtgcctgatcggt480
tgcaaaccgccgatcggtgaacactggggtaaaggttctccgtgcaccaacgttgctgtt540
aacccgggtgactgcccgccgctggaactgatcaacaccgttatccaggacggtgacatg600
gttgacaccggtttcggtgctatggacttcaccaccctgcaggctaacaaatctgaagtt660
ccgctggacatctgcacctctatctgcaaatacccggactacatcaaaatggtttctgaa720
ccgtacggtgactctctgttcttctacctgcgtcgtgaacagatgttcgttcgtcacctg780
ttcaaccgtgctggtgctgttggtgaaaacgttccggacgacctgtacatcaaaggttct840
ggttctaccgctaacctggcttcttctaactacttcccgaccccgtctggttctatggtt900
acctctgacgctcagatcttcaacaaaccgtactggctgcagcgtgctcagggtcacaac960
aacggtatctgctggggtaaccagctgttcgttaccgttgttgacaccacccgttctacc1020
aacatgtctctgtgcgctgctatctctacctctgaaaccacctacaaaaacaccaacttc1080
aaagaatacctgcgtcacggtgaagaatacgacctgcagttcatcttccagctgtgcaaa1140
atcaccctgaccgctgacgttatgacctacatccactctatgaactctaccatcctggaa1200
gactggaacttcggtctgcagccgccgccgggtggtaccctggaagacacctaccgtttc1260
gttacctctcaggctatcgcttgccagaaacacaccccgccggctccgaaagaagacccg1320
ctgaaaaaatacaccttctgggaagttaacctgaaagaaaaattctctgctgacctggac1380
cagttcccgctgggtcgtaaattcctgctgcaggctggtctgaaagctaaaccgaaattc1440
accctgggtaaacgtaaagctaccccgaccacctcttctacctctaccaccgctaaacgt1500
aaacagcgtaaactg1515
<210>3
<211>2208
<212>DNA
<213> artificial sequence
<400>3
atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60
ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120
tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180
ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240
atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300
gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360
gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420
acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480
gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540
aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600
tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660
ctggaagttctgttccaggggcccctgggatccatgtctctgtggctgccgtctgaagct720
accgtttacctgccgccggttccggtttctaaagttgtttctaccgacgaatacgttgct780
cgtaccaacatctactaccacgctggtacctctcgtctgctggctgttggtcacccgtac840
ttcccgatcaaaaaaccgaacaacaacaaaatcctggttccgaaagtttctggtctgcag900
taccgtgttttccgtatccacctgccggacccgaacaaattcggtttcccggacacctct960
ttctacaacccggacacccagcgtctggtttgggcttgcgttggtgttgaagttggtcgt1020
ggtcagccgctgggtgttggtatctctggtcacccgctgctgaacaaactggacgacacc1080
gaaaacgcttctgcttacgctgctaacgctggtgttgacaaccgtgaatgcatctctatg1140
gactacaaacagacccagctgtgcctgatcggttgcaaaccgccgatcggtgaacactgg1200
ggtaaaggttctccgtgcaccaacgttgctgttaacccgggtgactgcccgccgctggaa1260
ctgatcaacaccgttatccaggacggtgacatggttgacaccggtttcggtgctatggac1320
ttcaccaccctgcaggctaacaaatctgaagttccgctggacatctgcacctctatctgc1380
aaatacccggactacatcaaaatggtttctgaaccgtacggtgactctctgttcttctac1440
ctgcgtcgtgaacagatgttcgttcgtcacctgttcaaccgtgctggtgctgttggtgaa1500
aacgttccggacgacctgtacatcaaaggttctggttctaccgctaacctggcttcttct1560
aactacttcccgaccccgtctggttctatggttacctctgacgctcagatcttcaacaaa1620
ccgtactggctgcagcgtgctcagggtcacaacaacggtatctgctggggtaaccagctg1680
ttcgttaccgttgttgacaccacccgttctaccaacatgtctctgtgcgctgctatctct1740
acctctgaaaccacctacaaaaacaccaacttcaaagaatacctgcgtcacggtgaagaa1800
tacgacctgcagttcatcttccagctgtgcaaaatcaccctgaccgctgacgttatgacc1860
tacatccactctatgaactctaccatcctggaagactggaacttcggtctgcagccgccg1920
ccgggtggtaccctggaagacacctaccgtttcgttacctctcaggctatcgcttgccag1980
aaacacaccccgccggctccgaaagaagacccgctgaaaaaatacaccttctgggaagtt2040
aacctgaaagaaaaattctctgctgacctggaccagttcccgctgggtcgtaaattcctg2100
ctgcaggctggtctgaaagctaaaccgaaattcaccctgggtaaacgtaaagctaccccg2160
accacctcttctacctctaccaccgctaaacgtaaacagcgtaaactg2208
<210>4
<211>2490
<212>DNA
<213> artificial sequence
<400>4
atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60
ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120
tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180
ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240
atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300
gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360
gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420
acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480
gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540
aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600
tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660
ctggaagttctgttccaggggccctctgaccaggaagctaaaccgtctaccgaagacctg720
ggtgacaaaaaagaaggtgaatacatcaaactgaaagttatcggtcaggactcttctgaa780
atccacttcaaagttaaaatgaccacccacctgaaaaaactgaaagaatcttactgccag840
cgtcagggtgttccgatgaactctctgcgtttcctgttcgaaggtcagcgtatcgctgac900
aaccacaccccgaaagaactgggtatggaagaagaagacgttatcgaagtttaccaggaa960
cagaccggtggatccatgtctctgtggctgccgtctgaagctaccgtttacctgccgccg1020
gttccggtttctaaagttgtttctaccgacgaatacgttgctcgtaccaacatctactac1080
cacgctggtacctctcgtctgctggctgttggtcacccgtacttcccgatcaaaaaaccg1140
aacaacaacaaaatcctggttccgaaagtttctggtctgcagtaccgtgttttccgtatc1200
cacctgccggacccgaacaaattcggtttcccggacacctctttctacaacccggacacc1260
cagcgtctggtttgggcttgcgttggtgttgaagttggtcgtggtcagccgctgggtgtt1320
ggtatctctggtcacccgctgctgaacaaactggacgacaccgaaaacgcttctgcttac1380
gctgctaacgctggtgttgacaaccgtgaatgcatctctatggactacaaacagacccag1440
ctgtgcctgatcggttgcaaaccgccgatcggtgaacactggggtaaaggttctccgtgc1500
accaacgttgctgttaacccgggtgactgcccgccgctggaactgatcaacaccgttatc1560
caggacggtgacatggttgacaccggtttcggtgctatggacttcaccaccctgcaggct1620
aacaaatctgaagttccgctggacatctgcacctctatctgcaaatacccggactacatc1680
aaaatggtttctgaaccgtacggtgactctctgttcttctacctgcgtcgtgaacagatg1740
ttcgttcgtcacctgttcaaccgtgctggtgctgttggtgaaaacgttccggacgacctg1800
tacatcaaaggttctggttctaccgctaacctggcttcttctaactacttcccgaccccg1860
tctggttctatggttacctctgacgctcagatcttcaacaaaccgtactggctgcagcgt1920
gctcagggtcacaacaacggtatctgctggggtaaccagctgttcgttaccgttgttgac1980
accacccgttctaccaacatgtctctgtgcgctgctatctctacctctgaaaccacctac2040
aaaaacaccaacttcaaagaatacctgcgtcacggtgaagaatacgacctgcagttcatc2100
ttccagctgtgcaaaatcaccctgaccgctgacgttatgacctacatccactctatgaac2160
tctaccatcctggaagactggaacttcggtctgcagccgccgccgggtggtaccctggaa2220
gacacctaccgtttcgttacctctcaggctatcgcttgccagaaacacaccccgccggct2280
ccgaaagaagacccgctgaaaaaatacaccttctgggaagttaacctgaaagaaaaattc2340
tctgctgacctggaccagttcccgctgggtcgtaaattcctgctgcaggctggtctgaaa2400
gctaaaccgaaattcaccctgggtaaacgtaaagctaccccgaccacctcttctacctct2460
accaccgctaaacgtaaacagcgtaaactg2490
<210>5
<211>2688
<212>DNA
<213> artificial sequence
<400>5
atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt60
ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat120
ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt180
atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc240
accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac300
aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa360
gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg420
aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg480
ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa540
gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt600
aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa660
ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa720
gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt780
ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc840
ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg900
ggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgcc960
actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc1020
tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa1080
gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac1140
aacctcgggatcgagggaaggatttcagaattcatgtctctgtggctgccgtctgaagct1200
accgtttacctgccgccggttccggtttctaaagttgtttctaccgacgaatacgttgct1260
cgtaccaacatctactaccacgctggtacctctcgtctgctggctgttggtcacccgtac1320
ttcccgatcaaaaaaccgaacaacaacaaaatcctggttccgaaagtttctggtctgcag1380
taccgtgttttccgtatccacctgccggacccgaacaaattcggtttcccggacacctct1440
ttctacaacccggacacccagcgtctggtttgggcttgcgttggtgttgaagttggtcgt1500
ggtcagccgctgggtgttggtatctctggtcacccgctgctgaacaaactggacgacacc1560
gaaaacgcttctgcttacgctgctaacgctggtgttgacaaccgtgaatgcatctctatg1620
gactacaaacagacccagctgtgcctgatcggttgcaaaccgccgatcggtgaacactgg1680
ggtaaaggttctccgtgcaccaacgttgctgttaacccgggtgactgcccgccgctggaa1740
ctgatcaacaccgttatccaggacggtgacatggttgacaccggtttcggtgctatggac1800
ttcaccaccctgcaggctaacaaatctgaagttccgctggacatctgcacctctatctgc1860
aaatacccggactacatcaaaatggtttctgaaccgtacggtgactctctgttcttctac1920
ctgcgtcgtgaacagatgttcgttcgtcacctgttcaaccgtgctggtgctgttggtgaa1980
aacgttccggacgacctgtacatcaaaggttctggttctaccgctaacctggcttcttct2040
aactacttcccgaccccgtctggttctatggttacctctgacgctcagatcttcaacaaa2100
ccgtactggctgcagcgtgctcagggtcacaacaacggtatctgctggggtaaccagctg2160
ttcgttaccgttgttgacaccacccgttctaccaacatgtctctgtgcgctgctatctct2220
acctctgaaaccacctacaaaaacaccaacttcaaagaatacctgcgtcacggtgaagaa2280
tacgacctgcagttcatcttccagctgtgcaaaatcaccctgaccgctgacgttatgacc2340
tacatccactctatgaactctaccatcctggaagactggaacttcggtctgcagccgccg2400
ccgggtggtaccctggaagacacctaccgtttcgttacctctcaggctatcgcttgccag2460
aaacacaccccgccggctccgaaagaagacccgctgaaaaaatacaccttctgggaagtt2520
aacctgaaagaaaaattctctgctgacctggaccagttcccgctgggtcgtaaattcctg2580
ctgcaggctggtctgaaagctaaaccgaaattcaccctgggtaaacgtaaagctaccccg2640
accacctcttctacctctaccaccgctaaacgtaaacagcgtaaactg2688
<210>6
<211>1578
<212>DNA
<213> artificial sequence
<400>6
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat60
atgatgtctctgtggctgccgtctgaagctaccgtttacctgccgccggttccggtttct120
aaagttgtttctaccgacgaatacgttgctcgtaccaacatctactaccacgctggtacc180
tctcgtctgctggctgttggtcacccgtacttcccgatcaaaaaaccgaacaacaacaaa240
atcctggttccgaaagtttctggtctgcagtaccgtgttttccgtatccacctgccggac300
ccgaacaaattcggtttcccggacacctctttctacaacccggacacccagcgtctggtt360
tgggcttgcgttggtgttgaagttggtcgtggtcagccgctgggtgttggtatctctggt420
cacccgctgctgaacaaactggacgacaccgaaaacgcttctgcttacgctgctaacgct480
ggtgttgacaaccgtgaatgcatctctatggactacaaacagacccagctgtgcctgatc540
ggttgcaaaccgccgatcggtgaacactggggtaaaggttctccgtgcaccaacgttgct600
gttaacccgggtgactgcccgccgctggaactgatcaacaccgttatccaggacggtgac660
atggttgacaccggtttcggtgctatggacttcaccaccctgcaggctaacaaatctgaa720
gttccgctggacatctgcacctctatctgcaaatacccggactacatcaaaatggtttct780
gaaccgtacggtgactctctgttcttctacctgcgtcgtgaacagatgttcgttcgtcac840
ctgttcaaccgtgctggtgctgttggtgaaaacgttccggacgacctgtacatcaaaggt900
tctggttctaccgctaacctggcttcttctaactacttcccgaccccgtctggttctatg960
gttacctctgacgctcagatcttcaacaaaccgtactggctgcagcgtgctcagggtcac1020
aacaacggtatctgctggggtaaccagctgttcgttaccgttgttgacaccacccgttct1080
accaacatgtctctgtgcgctgctatctctacctctgaaaccacctacaaaaacaccaac1140
ttcaaagaatacctgcgtcacggtgaagaatacgacctgcagttcatcttccagctgtgc1200
aaaatcaccctgaccgctgacgttatgacctacatccactctatgaactctaccatcctg1260
gaagactggaacttcggtctgcagccgccgccgggtggtaccctggaagacacctaccgt1320
ttcgttacctctcaggctatcgcttgccagaaacacaccccgccggctccgaaagaagac1380
ccgctgaaaaaatacaccttctgggaagttaacctgaaagaaaaattctctgctgacctg1440
gaccagttcccgctgggtcgtaaattcctgctgcaggctggtctgaaagctaaaccgaaa1500
ttcaccctgggtaaacgtaaagctaccccgaccacctcttctacctctaccaccgctaaa1560
cgtaaacagcgtaaactg1578
<210>7
<211>1869
<212>DNA
<213> artificial sequence
<400>7
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat60
atgtctgaccaggaagctaaaccgtctaccgaagacctgggtgacaaaaaagaaggtgaa120
tacatcaaactgaaagttatcggtcaggactcttctgaaatccacttcaaagttaaaatg180
accacccacctgaaaaaactgaaagaatcttactgccagcgtcagggtgttccgatgaac240
tctctgcgtttcctgttcgaaggtcagcgtatcgctgacaaccacaccccgaaagaactg300
ggtatggaagaagaagacgttatcgaagtttaccaggaacagaccggtggatccatgtct360
ctgtggctgccgtctgaagctaccgtttacctgccgccggttccggtttctaaagttgtt420
tctaccgacgaatacgttgctcgtaccaacatctactaccacgctggtacctctcgtctg480
ctggctgttggtcacccgtacttcccgatcaaaaaaccgaacaacaacaaaatcctggtt540
ccgaaagtttctggtctgcagtaccgtgttttccgtatccacctgccggacccgaacaaa600
ttcggtttcccggacacctctttctacaacccggacacccagcgtctggtttgggcttgc660
gttggtgttgaagttggtcgtggtcagccgctgggtgttggtatctctggtcacccgctg720
ctgaacaaactggacgacaccgaaaacgcttctgcttacgctgctaacgctggtgttgac780
aaccgtgaatgcatctctatggactacaaacagacccagctgtgcctgatcggttgcaaa840
ccgccgatcggtgaacactggggtaaaggttctccgtgcaccaacgttgctgttaacccg900
ggtgactgcccgccgctggaactgatcaacaccgttatccaggacggtgacatggttgac960
accggtttcggtgctatggacttcaccaccctgcaggctaacaaatctgaagttccgctg1020
gacatctgcacctctatctgcaaatacccggactacatcaaaatggtttctgaaccgtac1080
ggtgactctctgttcttctacctgcgtcgtgaacagatgttcgttcgtcacctgttcaac1140
cgtgctggtgctgttggtgaaaacgttccggacgacctgtacatcaaaggttctggttct1200
accgctaacctggcttcttctaactacttcccgaccccgtctggttctatggttacctct1260
gacgctcagatcttcaacaaaccgtactggctgcagcgtgctcagggtcacaacaacggt1320
atctgctggggtaaccagctgttcgttaccgttgttgacaccacccgttctaccaacatg1380
tctctgtgcgctgctatctctacctctgaaaccacctacaaaaacaccaacttcaaagaa1440
tacctgcgtcacggtgaagaatacgacctgcagttcatcttccagctgtgcaaaatcacc1500
ctgaccgctgacgttatgacctacatccactctatgaactctaccatcctggaagactgg1560
aacttcggtctgcagccgccgccgggtggtaccctggaagacacctaccgtttcgttacc1620
tctcaggctatcgcttgccagaaacacaccccgccggctccgaaagaagacccgctgaaa1680
aaatacaccttctgggaagttaacctgaaagaaaaattctctgctgacctggaccagttc1740
ccgctgggtcgtaaattcctgctgcaggctggtctgaaagctaaaccgaaattcaccctg1800
ggtaaacgtaaagctaccccgaccacctcttctacctctaccaccgctaaacgtaaacag1860
cgtaaactg1869
<210>8
<211>736
<212>PRT
<213> artificial sequence
<400>8
MetSerProIleLeuGlyTyrTrpLysIleLysGlyLeuValGlnPro
151015
ThrArgLeuLeuLeuGluTyrLeuGluGluLysTyrGluGluHisLeu
202530
TyrGluArgAspGluGlyAspLysTrpArgAsnLysLysPheGluLeu
354045
GlyLeuGluPheProAsnLeuProTyrTyrIleAspGlyAspValLys
505560
LeuThrGlnSerMetAlaIleIleArgTyrIleAlaAspLysHisAsn
65707580
MetLeuGlyGlyCysProLysGluArgAlaGluIleSerMetLeuGlu
859095
GlyAlaValLeuAspIleArgTyrGlyValSerArgIleAlaTyrSer
100105110
LysAspPheGluThrLeuLysValAspPheLeuSerLysLeuProGlu
115120125
MetLeuLysMetPheGluAspArgLeuCysHisLysThrTyrLeuAsn
130135140
GlyAspHisValThrHisProAspPheMetLeuTyrAspAlaLeuAsp
145150155160
ValValLeuTyrMetAspProMetCysLeuAspAlaPheProLysLeu
165170175
ValCysPheLysLysArgIleGluAlaIleProGlnIleAspLysTyr
180185190
LeuLysSerSerLysTyrIleAlaTrpProLeuGlnGlyTrpGlnAla
195200205
ThrPheGlyGlyGlyAspHisProProLysSerAspLeuGluValLeu
210215220
PheGlnGlyProLeuGlySerMetSerLeuTrpLeuProSerGluAla
225230235240
ThrValTyrLeuProProValProValSerLysValValSerThrAsp
245250255
GluTyrValAlaArgThrAsnIleTyrTyrHisAlaGlyThrSerArg
260265270
LeuLeuAlaValGlyHisProTyrPheProIleLysLysProAsnAsn
275280285
AsnLysIleLeuValProLysValSerGlyLeuGlnTyrArgValPhe
290295300
ArgIleHisLeuProAspProAsnLysPheGlyPheProAspThrSer
305310315320
PheTyrAsnProAspThrGlnArgLeuValTrpAlaCysValGlyVal
325330335
GluValGlyArgGlyGlnProLeuGlyValGlyIleSerGlyHisPro
340345350
LeuLeuAsnLysLeuAspAspThrGluAsnAlaSerAlaTyrAlaAla
355360365
AsnAlaGlyValAspAsnArgGluCysIleSerMetAspTyrLysGln
370375380
ThrGlnLeuCysLeuIleGlyCysLysProProIleGlyGluHisTrp
385390395400
GlyLysGlySerProCysThrAsnValAlaValAsnProGlyAspCys
405410415
ProProLeuGluLeuIleAsnThrValIleGlnAspGlyAspMetVal
420425430
AspThrGlyPheGlyAlaMetAspPheThrThrLeuGlnAlaAsnLys
435440445
SerGluValProLeuAspIleCysThrSerIleCysLysTyrProAsp
450455460
TyrIleLysMetValSerGluProTyrGlyAspSerLeuPhePheTyr
465470475480
LeuArgArgGluGlnMetPheValArgHisLeuPheAsnArgAlaGly
485490495
AlaValGlyGluAsnValProAspAspLeuTyrIleLysGlySerGly
500505510
SerThrAlaAsnLeuAlaSerSerAsnTyrPheProThrProSerGly
515520525
SerMetValThrSerAspAlaGlnIlePheAsnLysProTyrTrpLeu
530535540
GlnArgAlaGlnGlyHisAsnAsnGlyIleCysTrpGlyAsnGlnLeu
545550555560
PheValThrValValAspThrThrArgSerThrAsnMetSerLeuCys
565570575
AlaAlaIleSerThrSerGluThrThrTyrLysAsnThrAsnPheLys
580585590
GluTyrLeuArgHisGlyGluGluTyrAspLeuGlnPheIlePheGln
595600605
LeuCysLysIleThrLeuThrAlaAspValMetThrTyrIleHisSer
610615620
MetAsnSerThrIleLeuGluAspTrpAsnPheGlyLeuGlnProPro
625630635640
ProGlyGlyThrLeuGluAspThrTyrArgPheValThrSerGlnAla
645650655
IleAlaCysGlnLysHisThrProProAlaProLysGluAspProLeu
660665670
LysLysTyrThrPheTrpGluValAsnLeuLysGluLysPheSerAla
675680685
AspLeuAspGlnPheProLeuGlyArgLysPheLeuLeuGlnAlaGly
690695700
LeuLysAlaLysProLysPheThrLeuGlyLysArgLysAlaThrPro
705710715720
ThrThrSerSerThrSerThrThrAlaLysArgLysGlnArgLysLeu
725730735
<210>9
<211>830
<212>PRT
<213> artificial sequence
<400>9
MetSerProIleLeuGlyTyrTrpLysIleLysGlyLeuValGlnPro
151015
ThrArgLeuLeuLeuGluTyrLeuGluGluLysTyrGluGluHisLeu
202530
TyrGluArgAspGluGlyAspLysTrpArgAsnLysLysPheGluLeu
354045
GlyLeuGluPheProAsnLeuProTyrTyrIleAspGlyAspValLys
505560
LeuThrGlnSerMetAlaIleIleArgTyrIleAlaAspLysHisAsn
65707580
MetLeuGlyGlyCysProLysGluArgAlaGluIleSerMetLeuGlu
859095
GlyAlaValLeuAspIleArgTyrGlyValSerArgIleAlaTyrSer
100105110
LysAspPheGluThrLeuLysValAspPheLeuSerLysLeuProGlu
115120125
MetLeuLysMetPheGluAspArgLeuCysHisLysThrTyrLeuAsn
130135140
GlyAspHisValThrHisProAspPheMetLeuTyrAspAlaLeuAsp
145150155160
ValValLeuTyrMetAspProMetCysLeuAspAlaPheProLysLeu
165170175
ValCysPheLysLysArgIleGluAlaIleProGlnIleAspLysTyr
180185190
LeuLysSerSerLysTyrIleAlaTrpProLeuGlnGlyTrpGlnAla
195200205
ThrPheGlyGlyGlyAspHisProProLysSerAspLeuGluValLeu
210215220
PheGlnGlyProSerAspGlnGluAlaLysProSerThrGluAspLeu
225230235240
GlyAspLysLysGluGlyGluTyrIleLysLeuLysValIleGlyGln
245250255
AspSerSerGluIleHisPheLysValLysMetThrThrHisLeuLys
260265270
LysLeuLysGluSerTyrCysGlnArgGlnGlyValProMetAsnSer
275280285
LeuArgPheLeuPheGluGlyGlnArgIleAlaAspAsnHisThrPro
290295300
LysGluLeuGlyMetGluGluGluAspValIleGluValTyrGlnGlu
305310315320
GlnThrGlyGlySerMetSerLeuTrpLeuProSerGluAlaThrVal
325330335
TyrLeuProProValProValSerLysValValSerThrAspGluTyr
340345350
ValAlaArgThrAsnIleTyrTyrHisAlaGlyThrSerArgLeuLeu
355360365
AlaValGlyHisProTyrPheProIleLysLysProAsnAsnAsnLys
370375380
IleLeuValProLysValSerGlyLeuGlnTyrArgValPheArgIle
385390395400
HisLeuProAspProAsnLysPheGlyPheProAspThrSerPheTyr
405410415
AsnProAspThrGlnArgLeuValTrpAlaCysValGlyValGluVal
420425430
GlyArgGlyGlnProLeuGlyValGlyIleSerGlyHisProLeuLeu
435440445
AsnLysLeuAspAspThrGluAsnAlaSerAlaTyrAlaAlaAsnAla
450455460
GlyValAspAsnArgGluCysIleSerMetAspTyrLysGlnThrGln
465470475480
LeuCysLeuIleGlyCysLysProProIleGlyGluHisTrpGlyLys
485490495
GlySerProCysThrAsnValAlaValAsnProGlyAspCysProPro
500505510
LeuGluLeuIleAsnThrValIleGlnAspGlyAspMetValAspThr
515520525
GlyPheGlyAlaMetAspPheThrThrLeuGlnAlaAsnLysSerGlu
530535540
ValProLeuAspIleCysThrSerIleCysLysTyrProAspTyrIle
545550555560
LysMetValSerGluProTyrGlyAspSerLeuPhePheTyrLeuArg
565570575
ArgGluGlnMetPheValArgHisLeuPheAsnArgAlaGlyAlaVal
580585590
GlyGluAsnValProAspAspLeuTyrIleLysGlySerGlySerThr
595600605
AlaAsnLeuAlaSerSerAsnTyrPheProThrProSerGlySerMet
610615620
ValThrSerAspAlaGlnIlePheAsnLysProTyrTrpLeuGlnArg
625630635640
AlaGlnGlyHisAsnAsnGlyIleCysTrpGlyAsnGlnLeuPheVal
645650655
ThrValValAspThrThrArgSerThrAsnMetSerLeuCysAlaAla
660665670
IleSerThrSerGluThrThrTyrLysAsnThrAsnPheLysGluTyr
675680685
LeuArgHisGlyGluGluTyrAspLeuGlnPheIlePheGlnLeuCys
690695700
LysIleThrLeuThrAlaAspValMetThrTyrIleHisSerMetAsn
705710715720
SerThrIleLeuGluAspTrpAsnPheGlyLeuGlnProProProGly
725730735
GlyThrLeuGluAspThrTyrArgPheValThrSerGlnAlaIleAla
740745750
CysGlnLysHisThrProProAlaProLysGluAspProLeuLysLys
755760765
TyrThrPheTrpGluValAsnLeuLysGluLysPheSerAlaAspLeu
770775780
AspGlnPheProLeuGlyArgLysPheLeuLeuGlnAlaGlyLeuLys
785790795800
AlaLysProLysPheThrLeuGlyLysArgLysAlaThrProThrThr
805810815
SerSerThrSerThrThrAlaLysArgLysGlnArgLysLeu
820825830
<210>10
<211>896
<212>PRT
<213> artificial sequence
<400>10
MetLysIleGluGluGlyLysLeuValIleTrpIleAsnGlyAspLys
151015
GlyTyrAsnGlyLeuAlaGluValGlyLysLysPheGluLysAspThr
202530
GlyIleLysValThrValGluHisProAspLysLeuGluGluLysPhe
354045
ProGlnValAlaAlaThrGlyAspGlyProAspIleIlePheTrpAla
505560
HisAspArgPheGlyGlyTyrAlaGlnSerGlyLeuLeuAlaGluIle
65707580
ThrProAspLysAlaPheGlnAspLysLeuTyrProPheThrTrpAsp
859095
AlaValArgTyrAsnGlyLysLeuIleAlaTyrProIleAlaValGlu
100105110
AlaLeuSerLeuIleTyrAsnLysAspLeuLeuProAsnProProLys
115120125
ThrTrpGluGluIleProAlaLeuAspLysGluLeuLysAlaLysGly
130135140
LysSerAlaLeuMetPheAsnLeuGlnGluProTyrPheThrTrpPro
145150155160
LeuIleAlaAlaAspGlyGlyTyrAlaPheLysTyrGluAsnGlyLys
165170175
TyrAspIleLysAspValGlyValAspAsnAlaGlyAlaLysAlaGly
180185190
LeuThrPheLeuValAspLeuIleLysAsnLysHisMetAsnAlaAsp
195200205
ThrAspTyrSerIleAlaGluAlaAlaPheAsnLysGlyGluThrAla
210215220
MetThrIleAsnGlyProTrpAlaTrpSerAsnIleAspThrSerLys
225230235240
ValAsnTyrGlyValThrValLeuProThrPheLysGlyGlnProSer
245250255
LysProPheValGlyValLeuSerAlaGlyIleAsnAlaAlaSerPro
260265270
AsnLysGluLeuAlaLysGluPheLeuGluAsnTyrLeuLeuThrAsp
275280285
GluGlyLeuGluAlaValAsnLysAspLysProLeuGlyAlaValAla
290295300
LeuLysSerTyrGluGluGluLeuAlaLysAspProArgIleAlaAla
305310315320
ThrMetGluAsnAlaGlnLysGlyGluIleMetProAsnIleProGln
325330335
MetSerAlaPheTrpTyrAlaValArgThrAlaValIleAsnAlaAla
340345350
SerGlyArgGlnThrValAspGluAlaLeuLysAspAlaGlnThrAsn
355360365
SerSerSerAsnAsnAsnAsnAsnAsnAsnAsnAsnAsnLeuGlyIle
370375380
GluGlyArgIleSerGluPheMetSerLeuTrpLeuProSerGluAla
385390395400
ThrValTyrLeuProProValProValSerLysValValSerThrAsp
405410415
GluTyrValAlaArgThrAsnIleTyrTyrHisAlaGlyThrSerArg
420425430
LeuLeuAlaValGlyHisProTyrPheProIleLysLysProAsnAsn
435440445
AsnLysIleLeuValProLysValSerGlyLeuGlnTyrArgValPhe
450455460
ArgIleHisLeuProAspProAsnLysPheGlyPheProAspThrSer
465470475480
PheTyrAsnProAspThrGlnArgLeuValTrpAlaCysValGlyVal
485490495
GluValGlyArgGlyGlnProLeuGlyValGlyIleSerGlyHisPro
500505510
LeuLeuAsnLysLeuAspAspThrGluAsnAlaSerAlaTyrAlaAla
515520525
AsnAlaGlyValAspAsnArgGluCysIleSerMetAspTyrLysGln
530535540
ThrGlnLeuCysLeuIleGlyCysLysProProIleGlyGluHisTrp
545550555560
GlyLysGlySerProCysThrAsnValAlaValAsnProGlyAspCys
565570575
ProProLeuGluLeuIleAsnThrValIleGlnAspGlyAspMetVal
580585590
AspThrGlyPheGlyAlaMetAspPheThrThrLeuGlnAlaAsnLys
595600605
SerGluValProLeuAspIleCysThrSerIleCysLysTyrProAsp
610615620
TyrIleLysMetValSerGluProTyrGlyAspSerLeuPhePheTyr
625630635640
LeuArgArgGluGlnMetPheValArgHisLeuPheAsnArgAlaGly
645650655
AlaValGlyGluAsnValProAspAspLeuTyrIleLysGlySerGly
660665670
SerThrAlaAsnLeuAlaSerSerAsnTyrPheProThrProSerGly
675680685
SerMetValThrSerAspAlaGlnIlePheAsnLysProTyrTrpLeu
690695700
GlnArgAlaGlnGlyHisAsnAsnGlyIleCysTrpGlyAsnGlnLeu
705710715720
PheValThrValValAspThrThrArgSerThrAsnMetSerLeuCys
725730735
AlaAlaIleSerThrSerGluThrThrTyrLysAsnThrAsnPheLys
740745750
GluTyrLeuArgHisGlyGluGluTyrAspLeuGlnPheIlePheGln
755760765
LeuCysLysIleThrLeuThrAlaAspValMetThrTyrIleHisSer
770775780
MetAsnSerThrIleLeuGluAspTrpAsnPheGlyLeuGlnProPro
785790795800
ProGlyGlyThrLeuGluAspThrTyrArgPheValThrSerGlnAla
805810815
IleAlaCysGlnLysHisThrProProAlaProLysGluAspProLeu
820825830
LysLysTyrThrPheTrpGluValAsnLeuLysGluLysPheSerAla
835840845
AspLeuAspGlnPheProLeuGlyArgLysPheLeuLeuGlnAlaGly
850855860
LeuLysAlaLysProLysPheThrLeuGlyLysArgLysAlaThrPro
865870875880
ThrThrSerSerThrSerThrThrAlaLysArgLysGlnArgLysLeu
885890895
<210>11
<211>2097
<212>DNA
<213> artificial sequence
<400>11
atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60
ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120
tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180
ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240
atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300
gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360
gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420
acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480
gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540
aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600
tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660
ctggaagttctgttccaggggccctctgaagctaccgtttacctgccgccggttccggtt720
tctaaagttgtttctaccgacgaatacgttgctcgtaccaacatctactaccacgctggt780
acctctcgtctgctggctgttggtcacccgtacttcccgatcaaaaaaccgaacaacaac840
aaaatcctggttccgaaagtttctggtctgcagtaccgtgttttccgtatccacctgccg900
gacccgaacaaattcggtttcccggacacctctttctacaacccggacacccagcgtctg960
gtttgggcttgcgttggtgttgaagttggtcgtggtcagccgctgggtgttggtatctct1020
ggtcacccgctgctgaacaaactggacgacaccgaaaacgcttctgcttacgctgctaac1080
gctggtgttgacaaccgtgaatgcatctctatggactacaaacagacccagctgtgcctg1140
atcggttgcaaaccgccgatcggtgaacactggggtaaaggttctccgtgcaccaacgtt1200
gctgttaacccgggtgactgcccgccgctggaactgatcaacaccgttatccaggacggt1260
gacatggttgacaccggtttcggtgctatggacttcaccaccctgcaggctaacaaatct1320
gaagttccgctggacatctgcacctctatctgcaaatacccggactacatcaaaatggtt1380
tctgaaccgtacggtgactctctgttcttctacctgcgtcgtgaacagatgttcgttcgt1440
cacctgttcaaccgtgctggtgctgttggtgaaaacgttccggacgacctgtacatcaaa1500
ggttctggttctaccgctaacctggcttcttctaactacttcccgaccccgtctggttct1560
atggttacctctgacgctcagatcttcaacaaaccgtactggctgcagcgtgctcagggt1620
cacaacaacggtatctgctggggtaaccagctgttcgttaccgttgttgacaccacccgt1680
tctaccaacatgtctctgtgcgctgctatctctacctctgaaaccacctacaaaaacacc1740
aacttcaaagaatacctgcgtcacggtgaagaatacgacctgcagttcatcttccagctg1800
tgcaaaatcaccctgaccgctgacgttatgacctacatccactctatgaactctaccatc1860
ctggaagactggaacttcggtctgcagccgccgccgggtggtaccctggaagacacctac1920
cgtttcgttacctctcaggctatcgcttgccagaaacacaccccgccggctccgaaagaa1980
gacccgctgaaaaaatacaccttctgggaagttaacctgaaagaaaaattctctgctgac2040
ctggaccagttcccgctgggtcgtaaattcctgctgcaggctggtctgaaagcttag2097
<210>12
<211>2472
<212>DNA
<213> artificial sequence
<400>12
atgtcccctatactaggttattggaaaattaagggccttgtgcaacccactcgacttctt60
ttggaatatcttgaagaaaaatatgaagagcatttgtatgagcgcgatgaaggtgataaa120
tggcgaaacaaaaagtttgaattgggtttggagtttcccaatcttccttattatattgat180
ggtgatgttaaattaacacagtctatggccatcatacgttatatagctgacaagcacaac240
atgttgggtggttgtccaaaagagcgtgcagagatttcaatgcttgaaggagcggttttg300
gatattagatacggtgtttcgagaattgcatatagtaaagactttgaaactctcaaagtt360
gattttcttagcaagctacctgaaatgctgaaaatgttcgaagatcgtttatgtcataaa420
acatatttaaatggtgatcatgtaacccatcctgacttcatgttgtatgacgctcttgat480
gttgttttatacatggacccaatgtgcctggatgcgttcccaaaattagtttgttttaaa540
aaacgtattgaagctatcccacaaattgataagtacttgaaatccagcaagtatatagca600
tggcctttgcagggctggcaagccacgtttggtggtggcgaccatcctccaaaatcggat660
ctggaagttctgttccaggggccctctgaccaggaagctaaaccgtctaccgaagacctg720
ggtgacaaaaaagaaggtgaatacatcaaactgaaagttatcggtcaggactcttctgaa780
atccacttcaaagttaaaatgaccacccacctgaaaaaactgaaagaatcttactgccag840
cgtcagggtgttccgatgaactctctgcgtttcctgttcgaaggtcagcgtatcgctgac900
aaccacaccccgaaagaactgggtatggaagaagaagacgttatcgaagtttaccaggaa960
cagaccggtggatcctctgaagctaccgtttacctgccgccggttccggtttctaaagtt1020
gtttctaccgacgaatacgttgctcgtaccaacatctactaccacgctggtacctctcgt1080
ctgctggctgttggtcacccgtacttcccgatcaaaaaaccgaacaacaacaaaatcctg1140
gttccgaaagtttctggtctgcagtaccgtgttttccgtatccacctgccggacccgaac1200
aaattcggtttcccggacacctctttctacaacccggacacccagcgtctggtttgggct1260
tgcgttggtgttgaagttggtcgtggtcagccgctgggtgttggtatctctggtcacccg1320
ctgctgaacaaactggacgacaccgaaaacgcttctgcttacgctgctaacgctggtgtt1380
gacaaccgtgaatgcatctctatggactacaaacagacccagctgtgcctgatcggttgc1440
aaaccgccgatcggtgaacactggggtaaaggttctccgtgcaccaacgttgctgttaac1500
ccgggtgactgcccgccgctggaactgatcaacaccgttatccaggacggtgacatggtt1560
gacaccggtttcggtgctatggacttcaccaccctgcaggctaacaaatctgaagttccg1620
ctggacatctgcacctctatctgcaaatacccggactacatcaaaatggtttctgaaccg1680
tacggtgactctctgttcttctacctgcgtcgtgaacagatgttcgttcgtcacctgttc1740
aaccgtgctggtgctgttggtgaaaacgttccggacgacctgtacatcaaaggttctggt1800
tctaccgctaacctggcttcttctaactacttcccgaccccgtctggttctatggttacc1860
tctgacgctcagatcttcaacaaaccgtactggctgcagcgtgctcagggtcacaacaac1920
ggtatctgctggggtaaccagctgttcgttaccgttgttgacaccacccgttctaccaac1980
atgtctctgtgcgctgctatctctacctctgaaaccacctacaaaaacaccaacttcaaa2040
gaatacctgcgtcacggtgaagaatacgacctgcagttcatcttccagctgtgcaaaatc2100
accctgaccgctgacgttatgacctacatccactctatgaactctaccatcctggaagac2160
tggaacttcggtctgcagccgccgccgggtggtaccctggaagacacctaccgtttcgtt2220
acctctcaggctatcgcttgccagaaacacaccccgccggctccgaaagaagacccgctg2280
aaaaaatacaccttctgggaagttaacctgaaagaaaaattctctgctgacctggaccag2340
ttcccgctgggtcgtaaattcctgctgcaggctggtctgaaagctaaaccgaaattcacc2400
ctgggtaaacgtaaagctaccccgaccacctcttctacctctaccaccgctaaacgtaaa2460
cagcgtaaactg2472
<210>13
<211>2643
<212>DNA
<213> artificial sequence
<400>13
atgaaaatcgaagaaggtaaactggtaatctggattaacggcgataaaggctataacggt60
ctcgctgaagtcggtaagaaattcgagaaagataccggaattaaagtcaccgttgagcat120
ccggataaactggaagagaaattcccacaggttgcggcaactggcgatggccctgacatt180
atcttctgggcacacgaccgctttggtggctacgctcaatctggcctgttggctgaaatc240
accccggacaaagcgttccaggacaagctgtatccgtttacctgggatgccgtacgttac300
aacggcaagctgattgcttacccgatcgctgttgaagcgttatcgctgatttataacaaa360
gatctgctgccgaacccgccaaaaacctgggaagagatcccggcgctggataaagaactg420
aaagcgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacctggccg480
ctgattgctgctgacgggggttatgcgttcaagtatgaaaacggcaagtacgacattaaa540
gacgtgggcgtggataacgctggcgcgaaagcgggtctgaccttcctggttgacctgatt600
aaaaacaaacacatgaatgcagacaccgattactccatcgcagaagctgcctttaataaa660
ggcgaaacagcgatgaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaa720
gtgaattatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccgttcgtt780
ggcgtgctgagcgcaggtattaacgccgccagtccgaacaaagagctggcaaaagagttc840
ctcgaaaactatctgctgactgatgaaggtctggaagcggttaataaagacaaaccgctg900
ggtgccgtagcgctgaagtcttacgaggaagagttggcgaaagatccacgtattgccgcc960
actatggaaaacgcccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttc1020
tggtatgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtcgatgaa1080
gccctgaaagacgcgcagactaattcgagctcgaacaacaacaacaataacaataacaac1140
aacctcgggatcgagggaaggatttcagaattcatgtctctgtggctgccgtctgaagct1200
accgtttacctgccgccggttccggtttctaaagttgtttctaccgacgaatacgttgct1260
cgtaccaacatctactaccacgctggtacctctcgtctgctggctgttggtcacccgtac1320
ttcccgatcaaaaaaccgaacaacaacaaaatcctggttccgaaagtttctggtctgcag1380
taccgtgttttccgtatccacctgccggacccgaacaaattcggtttcccggacacctct1440
ttctacaacccggacacccagcgtctggtttgggcttgcgttggtgttgaagttggtcgt1500
ggtcagccgctgggtgttggtatctctggtcacccgctgctgaacaaactggacgacacc1560
gaaaacgcttctgcttacgctgctaacgctggtgttgacaaccgtgaatgcatctctatg1620
gactacaaacagacccagctgtgcctgatcggttgcaaaccgccgatcggtgaacactgg1680
ggtaaaggttctccgtgcaccaacgttgctgttaacccgggtgactgcccgccgctggaa1740
ctgatcaacaccgttatccaggacggtgacatggttgacaccggtttcggtgctatggac1800
ttcaccaccctgcaggctaacaaatctgaagttccgctggacatctgcacctctatctgc1860
aaatacccggactacatcaaaatggtttctgaaccgtacggtgactctctgttcttctac1920
ctgcgtcgtgaacagatgttcgttcgtcacctgttcaaccgtgctggtgctgttggtgaa1980
aacgttccggacgacctgtacatcaaaggttctggttctaccgctaacctggcttcttct2040
aactacttcccgaccccgtctggttctatggttacctctgacgctcagatcttcaacaaa2100
ccgtactggctgcagcgtgctcagggtcacaacaacggtatctgctggggtaaccagctg2160
ttcgttaccgttgttgacaccacccgttctaccaacatgtctctgtgcgctgctatctct2220
acctctgaaaccacctacaaaaacaccaacttcaaagaatacctgcgtcacggtgaagaa2280
tacgacctgcagttcatcttccagctgtgcaaaatcaccctgaccgctgacgttatgacc2340
tacatccactctatgaactctaccatcctggaagactggaacttcggtctgcagccgccg2400
ccgggtggtaccctggaagacacctaccgtttcgttacctctcaggctatcgcttgccag2460
aaacacaccccgccggctccgaaagaagacccgctgaaaaaatacaccttctgggaagtt2520
aacctgaaagaaaaattctctgctgacctggaccagttcccgctgggtcgtaaattcctg2580
ctgcaggctggtctgaaagctaaaccgaaattcaccctgggtaaacgtaaagctaccccg2640
acc2643
Claims (21)
1., through a gene of the encoding human papilloma virus HPV16L1 of intestinal bacteria preferred codons optimization, this gene is the nucleotide sequence shown in SEQNO.2.
2. a coli expression carrier, is characterized in that this carrier comprises the sequence with gene described in claim 1.
3. coli expression carrier as claimed in claim 2, is characterized in that this carrier is pGEX-6p-1, pGEX-4T-2, pMAL or pET28a.
4. an engineering bacteria cell, this cell comprises gene according to claim 1, or the expression vector described in claim 2,3.
5. the fusion rotein of a Tag-HPV16L1, it is characterized in that this albumen comprises the gene of encoding human papilloma virus HPV16L1, preferably through the gene of the encoding human papilloma virus HPV16L1 of intestinal bacteria preferred codons optimization, more preferably genes encoding as claimed in claim 1; Label Tag is GST.Tag, MBP.Tag or GST-SUMO.Tag.
6. fusion rotein as claimed in claim 5, is characterized in that L1 protein is that full length protein or C hold no more than 30 amino acid of brachymemma and/or N to hold no more than 10 the amino acid whose L1 protein of brachymemma.
7. fusion rotein as claimed in claim 5, is characterized in that its nucleotides sequence is classified as SEQNO.3, SEQNO.4, SEQNO.5, SEQNO.11, SEQNO.12 or SEQNO.13.
8. fusion rotein as claimed in claim 5, is characterized in that its aminoacid sequence is SEQNO.8, SEQNO.9 or SEQNO.10.
9. a HPV16L1 pentamer protein, is characterized in that this pentamer protein is obtained after purifying by the fused protein as described in claim 5,6,7 or 8, pentamer albumen median size 10 ~ 15nmPdI<0.1.
10. a VLP of HPV16L1, is characterized in that this VLP is formed by pentamer protein assembly according to claim 9, median size 45 ~ 65nmPdI<0.1.
11. 1 kinds of HPVL1 protein vaccine compositions, is characterized in that this vaccine composition comprises HPVL1 pentamer protein according to claim 9 and medicinal adjuvant.
12. a HPVL1 protein vaccine composition, it is characterized in that this vaccine composition comprises HPVL1VLP according to claim 10 and medicinal adjuvant.
The preparation method of 13. fusion roteins as described in claim 5,6,7 or 8, is characterized in that the method comprises the steps:
By replacing the codon of HPV16L1 gene order with the codon of intestinal bacteria preference, obtain the gene of codon optimized HPV16L1;
Build the coli expression carrier of HPV16L1 gene;
Build the escherichia coli expression engineering strain of Tag-HPV16L1;
Abduction delivering purifying obtains fusion rotein Tag-HPV16L1.
14. method as claimed in claim 13, wherein said prokaryotic host cell is GI698, ER2566, BL21 (DE3), XA90, B834 (DE3) or BLR (DE3), preferred BL21 (DE3).
The preparation method of 15. HPV16L1 pentamer protein as claimed in claim 9, is characterized in that the method comprises the steps:
With affinity chromatography method absorption fusion rotein Tag-HPV16L1;
Add proteolytic enzyme excision Tag label, obtain HPV16L1 pentamer protein;
Purifying HPVL1 pentamer protein, the L1 pentamer protein of purity >98%, median size 10 ~ 15nmPdI<0.1.
The preparation method of 16. HPV16L1 pentamer protein as claimed in claim 15, is characterized in that described proteolytic enzyme is the site-specific proteolytic enzyme of excision Tag label: restructuring HRV 3CP, zymoplasm, SUMO proteolytic enzyme, SENP1 or TEV protease.
The preparation method of 17. HPV16L1VLP as claimed in claim 10, is characterized in that the method comprises the steps:
The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is mixed with assembling damping fluid, final acquisition pH value is 5.0 ~ 5.9, salt concn is 500 ~ 2000mM, the HPV16L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.
18. a preparation method of HPV16L1-VLP as claimed in claim 10 is assembled in cryogenic freezing process, it is characterized in that the method comprises the steps:
The L1 pentamer protein liquid of median size 10 ~ 15nmPdI<0.1 is placed in pH value is 5.5 ~ 8.0 salt concn is damping fluid under 150 ~ 1000mM condition, completely freezing under-20 ~-80 DEG C of conditions, place room temperature again to melt to protein stoste, obtain the HPV16L1VLP protein liquid of median size 45 ~ 65nmPdI<0.1.
19. the application of HPV16L1 pentamer protein as claimed in claim 9 in the medicine of preparation prevention HPV16 infection.
20. the application of HPV16L1VLP protein as claimed in claim 10 in the medicine of preparation prevention HPV16 infection.
Application in the medicine that 21. vaccine compositions as described in claim 11 or 12 infect at preparation prevention HPV16.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410683185.0A CN105039359B (en) | 2013-12-03 | 2014-11-25 | 16 type recombinant human papilloma virus-like particle and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310635249 | 2013-12-03 | ||
| CN2013106352495 | 2013-12-03 | ||
| CN201410683185.0A CN105039359B (en) | 2013-12-03 | 2014-11-25 | 16 type recombinant human papilloma virus-like particle and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105039359A true CN105039359A (en) | 2015-11-11 |
| CN105039359B CN105039359B (en) | 2020-02-28 |
Family
ID=54216657
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410672161.5A Active CN105039358B (en) | 2013-12-03 | 2014-11-22 | 58 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410672158.3A Active CN105177025B (en) | 2013-12-03 | 2014-11-22 | 18 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410672159.8A Active CN105002190B (en) | 2013-12-03 | 2014-11-22 | 11 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410685769.1A Active CN104962567B (en) | 2013-12-03 | 2014-11-25 | 6 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410683185.0A Active CN105039359B (en) | 2013-12-03 | 2014-11-25 | 16 type recombinant human papilloma virus-like particle and preparation method thereof |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410672161.5A Active CN105039358B (en) | 2013-12-03 | 2014-11-22 | 58 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410672158.3A Active CN105177025B (en) | 2013-12-03 | 2014-11-22 | 18 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410672159.8A Active CN105002190B (en) | 2013-12-03 | 2014-11-22 | 11 type recombinant human papilloma virus-like particle and preparation method thereof |
| CN201410685769.1A Active CN104962567B (en) | 2013-12-03 | 2014-11-25 | 6 type recombinant human papilloma virus-like particle and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (5) | CN105039358B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296521A (en) * | 2015-12-07 | 2016-02-03 | 郑州大学 | Recombinant plasmid capable of expressing soluble human papilloma virus 16 subtype L1 protein and expression method thereof |
| CN107188932A (en) * | 2016-03-15 | 2017-09-22 | 中国医学科学院基础医学研究所 | Truncated-type L 1 Protein of Human Papillomavirus Type 16 albumen and its application |
| CN108239652A (en) * | 2016-12-27 | 2018-07-03 | 天津大学 | Zika virus capsid protein rigidity fusion expression vector and structure and application |
| WO2021013063A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 16 l1 protein |
| CN114681602A (en) * | 2020-12-25 | 2022-07-01 | 中国食品药品检定研究院 | Bivalent human papilloma virus vaccine |
| CN116200416A (en) * | 2023-02-15 | 2023-06-02 | 北京康乐卫士生物技术股份有限公司 | Construction and application of plasmid expression vector based on Tac promoter |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105548420B (en) * | 2015-12-30 | 2019-08-02 | 上海泽润生物科技有限公司 | The detection method of MOPS residual quantity |
| CN107188931B (en) * | 2016-03-15 | 2020-02-11 | 中国医学科学院基础医学研究所 | Truncated human papilloma virus 58 type L1 protein and application thereof |
| JP7051132B2 (en) * | 2016-09-16 | 2022-04-11 | ロイコケア・アクチェンゲゼルシャフト | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
| CN107488747A (en) * | 2017-09-14 | 2017-12-19 | 温州美众医学检验所 | Quantitative fluorescent PCR primer and probe combinations and its reaction system |
| CN114539363B (en) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | C-terminal modified human papilloma virus 11 type L1 protein and application thereof |
| CN113549634B (en) * | 2021-06-07 | 2023-03-31 | 郑州大学 | Gene for coding soluble HPV58L1 protein and construction and application of recombinant plasmid thereof |
| CN116023446A (en) * | 2022-10-28 | 2023-04-28 | 北京康乐卫士生物技术股份有限公司 | Expression of human papilloma virus HPV68L1 protein, viroid particle and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259051A (en) * | 1997-04-08 | 2000-07-05 | 麦克公司 | Stabilized human papillomavirus formulations |
| CN101016542A (en) * | 2007-02-14 | 2007-08-15 | 马润林 | Method of increasing yield of human papilloma virus L1 albumen pronucleus expression |
| CN101245099A (en) * | 2007-02-14 | 2008-08-20 | 马润林 | Amino acid sequence of recombined human papilloma virus L1 capsid protein and uses thereof |
| CN101293918A (en) * | 2007-04-29 | 2008-10-29 | 北京万泰生物药业股份有限公司 | Shorten human papilloma virus 16 type L1 protein |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7816399B2 (en) * | 2001-04-19 | 2010-10-19 | Teika Pharmaceutical Co., Ltd. | Medicines and medicinal kits |
| CN101153280B (en) * | 2006-09-29 | 2015-08-19 | 厦门大学 | The method of purifying human papilloma virus advanced protein L1 from prokaryotic organism |
| WO2008134935A1 (en) * | 2007-04-29 | 2008-11-13 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated human papillomavirus type 18 l1 proteins |
| WO2008145021A1 (en) * | 2007-05-29 | 2008-12-04 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
| EP2154148B1 (en) * | 2007-05-29 | 2016-06-22 | Xiamen University | A truncated l1 protein of human papillomavirus 11 |
| CN101481407A (en) * | 2008-01-07 | 2009-07-15 | 马润林 | Modification sequence of recombinant human mammilla tumor virus L1 capsid protein |
| CN101735310B (en) * | 2008-11-20 | 2012-07-18 | 中国疾病预防控制中心病毒病预防控制所 | Human papilloma virus (HPV) fusion protein, gene, carrier, strain, preparation method and application |
| JP6189748B2 (en) * | 2010-05-05 | 2017-08-30 | ドイチェス クレブスフォルシュングスツェントルム | HR-HPV diagnostic transcripts and splice patterns in various cervical lesions |
| CN101857870B (en) * | 2010-06-12 | 2012-09-05 | 上海泽润生物科技有限公司 | HPV58 L1 gene, vector, strain and expression method |
| BR112013000996B1 (en) * | 2010-07-16 | 2021-08-10 | Xiamen Innovax Biotech Co., Ltd. | HPV58 TRUNCATE L1 PROTEIN, ISOLATED NUCLEIC ACID, VECTOR, HOST CELL, HPV58 VIRAL TYPE Particle, COMPOSITION, PHARMACEUTICAL COMPOSITION OR VACCINE, METHOD FOR OBTAINING A TRUNCATED HPV58 L1 PROTEIN, METHOD TO PREPARE A TIPO58 TI-PARTI VACCINE, AND USE OF TRUNCATE L1 HPV58 PROTEIN |
| WO2012158639A2 (en) * | 2011-05-14 | 2012-11-22 | Sanofi Pasteur Biologics, Llc | Recombinant fusion proteins and methods for use thereof for treatment or prevention of papillomavirus infection |
| CN103864936B (en) * | 2012-12-11 | 2018-01-23 | 中国疾病预防控制中心病毒病预防控制所 | HPV18 type L2NE7E6 antigen-4 fusion protein genes, expression vector, method, bacterial strain and purposes |
| CN104045696B (en) * | 2012-12-18 | 2018-10-19 | 北京康乐卫士生物技术股份有限公司 | L 1 Protein of Human Papillomavirus Type 16 of recombination and application thereof |
| CN104045695B (en) * | 2012-12-19 | 2019-01-25 | 北京康乐卫士生物技术股份有限公司 | HPV 18 L1 albumen of recombination and application thereof |
-
2014
- 2014-11-22 CN CN201410672161.5A patent/CN105039358B/en active Active
- 2014-11-22 CN CN201410672158.3A patent/CN105177025B/en active Active
- 2014-11-22 CN CN201410672159.8A patent/CN105002190B/en active Active
- 2014-11-25 CN CN201410685769.1A patent/CN104962567B/en active Active
- 2014-11-25 CN CN201410683185.0A patent/CN105039359B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259051A (en) * | 1997-04-08 | 2000-07-05 | 麦克公司 | Stabilized human papillomavirus formulations |
| CN101016542A (en) * | 2007-02-14 | 2007-08-15 | 马润林 | Method of increasing yield of human papilloma virus L1 albumen pronucleus expression |
| CN101245099A (en) * | 2007-02-14 | 2008-08-20 | 马润林 | Amino acid sequence of recombined human papilloma virus L1 capsid protein and uses thereof |
| CN101293918A (en) * | 2007-04-29 | 2008-10-29 | 北京万泰生物药业股份有限公司 | Shorten human papilloma virus 16 type L1 protein |
Non-Patent Citations (4)
| Title |
|---|
| CHEN XS ET AL: "Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16", 《MOLECULAR CELL》 * |
| 彭司勋: "《中国药学年鉴 2008》", 31 January 2009 * |
| 汪世龙: "《蛋白质化学》", 31 August 2012 * |
| 田锦: "《基因操作技术》", 31 August 2013 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105296521A (en) * | 2015-12-07 | 2016-02-03 | 郑州大学 | Recombinant plasmid capable of expressing soluble human papilloma virus 16 subtype L1 protein and expression method thereof |
| CN105296521B (en) * | 2015-12-07 | 2020-08-28 | 郑州大学 | Recombinant plasmid for expressing soluble human papilloma virus 16 subtype L1 protein and expression method thereof |
| CN107188932A (en) * | 2016-03-15 | 2017-09-22 | 中国医学科学院基础医学研究所 | Truncated-type L 1 Protein of Human Papillomavirus Type 16 albumen and its application |
| CN107188932B (en) * | 2016-03-15 | 2020-02-11 | 中国医学科学院基础医学研究所 | Truncated human papilloma virus 16 type L1 protein and application thereof |
| CN108239652A (en) * | 2016-12-27 | 2018-07-03 | 天津大学 | Zika virus capsid protein rigidity fusion expression vector and structure and application |
| CN108239652B (en) * | 2016-12-27 | 2020-03-17 | 天津大学 | Zika virus capsid protein rigid fusion expression vector and construction and application thereof |
| WO2021013063A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 16 l1 protein |
| CN114681602A (en) * | 2020-12-25 | 2022-07-01 | 中国食品药品检定研究院 | Bivalent human papilloma virus vaccine |
| CN114681602B (en) * | 2020-12-25 | 2023-12-01 | 中国食品药品检定研究院 | Bivalent human papillomavirus vaccine |
| CN116200416A (en) * | 2023-02-15 | 2023-06-02 | 北京康乐卫士生物技术股份有限公司 | Construction and application of plasmid expression vector based on Tac promoter |
| CN116200416B (en) * | 2023-02-15 | 2024-03-12 | 北京康乐卫士生物技术股份有限公司 | Construction and application of plasmid expression vector based on Tac promoter |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105039358B (en) | 2020-02-28 |
| CN105177025A (en) | 2015-12-23 |
| CN105039359B (en) | 2020-02-28 |
| CN105002190B (en) | 2022-11-08 |
| CN105002190A (en) | 2015-10-28 |
| CN105039358A (en) | 2015-11-11 |
| CN104962567B (en) | 2022-11-08 |
| CN104962567A (en) | 2015-10-07 |
| CN105177025B (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105039359A (en) | Virus-like particles of 16-type recombinant human papilloma virus and preparation method thereof | |
| CN101293918B (en) | Shorten human papilloma virus 16 type L1 protein | |
| JP3958360B2 (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
| CN102229660B (en) | Truncated human papillomavirus 33 type L1 protein | |
| CN101343314B (en) | The Human Papillomavirus Type 11 L1 albumen of brachymemma | |
| WO2008098484A1 (en) | Recombinant l1 proteins of human papilloma virus and uses thereof | |
| EP1305039B1 (en) | Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof | |
| CN101343315B (en) | Shorten human papilloma virus 6 type L1 protein | |
| CN103936840B (en) | Human papillomavirus 33 type L 1 protein of recombination and application thereof | |
| CN106831959A (en) | A kind of mutant of human papillomavirus 33 type L 1 protein | |
| CN101570571B (en) | Truncated human papilloma virus 18 type L1 protein | |
| CN106399329B (en) | 33 type recombinant human papilloma virus-like particle and preparation method thereof | |
| CN104212818B (en) | Optimized gene sequence of human papillomavirus 31 type L1 protein | |
| CN102336822B (en) | The human papillomavirus type 58 L1 albumen of brachymemma | |
| CN106701797B (en) | 31 type recombinant human papilloma virus-like particle and preparation method thereof | |
| WO2016026401A1 (en) | Method for enhancing hpv epitope peptide immunogenicity, viroid particle, particle preparation method and application | |
| CN106701796B (en) | 52 type recombinant human papilloma virus-like particle and preparation method thereof | |
| CN103992395A (en) | VLP vaccine of recombinant HPV-58 L1 and preparation method thereof | |
| CN103819543A (en) | Recombinant protein HPV6L1 (Human Papilloma Virus 6 L1) and application thereof | |
| CN104211782A (en) | Truncated human papillomavirus 45 type L1 protein | |
| CN104045696A (en) | Recombinant human papilloma virus 16L1 protein and its use | |
| CN104045695B (en) | HPV 18 L1 albumen of recombination and application thereof | |
| CN106701798B (en) | 45 type recombinant human papilloma virus-like particle and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |